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In compliance with the Terms of Reference <see Appendix 
A> the Report focuses on biotechnology and development. 
In order to properly assess IDRC and its position on 
biotechnology, Section 1 locates biotechnology in the 
appropriate historical, science and technology, and 
developmental context. Section 2 discusses general and 
divisional developments at IDRC with regards to 
biotechnology and development. Canadian federal 
government policy developments in the area of 
biotechnology are covered in Section 3. Sections 4 
provides a summary of policy developments and re~earch 
initiative of donor agencies and international 
institutional initiative related to biotechnology that 
address the issues relevant to the developing countries. 
Finally, Section 5 raises several obvious short-term and 
more fundamental longer-term issues arising out of the 
nature of biotechnology, its potential, and trends in 
biotechnology research. 
I like to acknowledge and express my thanks for the 
sincere and forthcoming support, assistance, cooperation 
and advice extended by IDRC management, officers and 
staff at all levels in the preparation of this Report. 
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Biotechnology is frequently described as part of the third 
industrial revolution together with micro-electronics. The 
revolutionary character of biotechnology is the fact that many of 
its varied applications are concerned with basic human needs. The 
impact of biotechnology is likely to be felt in many sectors, in 
agriculture and fisheries, human health care, environmental 
protection, energy, mining and industry. 
Biotechnology holds great promise for humankind: it could 
put an end to famine; it could provide answers to diseases such 
as malaria, hepatitis-B and AIDS; it could solve problems of 
waste disposal; and it could help in the fight against 
deforestation and high energy costs. In particular, biotechnology 
could help to solve problems in developing countries. 
Modern biotechnological research generally requires highly 
trained specialist researchers and large capital inv~stments but, 
the application of biotechnology is often uncomplicated and non-
capital intensive. Further, biotechnology applications do not 
usually require much energy. Use of these techniques is often 
highly flexible, and they can therefore be readily adapted to the 
specific conditions prevailing in developing countries. 
Although biotechnology offers many new opportunities for 
developing countries, especially in the long term, its 
application also entails disadvantages. Several developments in 
the field of biotechnology can have predominantly negative socio-
economic consequences for developing countries <e.g. substitution 
of raw materials, industrialization of agriculture and technology 
privatization>. Biotechnology can also have negative consequences 
for humankind and environment, and in the case of the developing 
countries, these problems may be compounded by their economic 
weakness and limited legislation. 
It will be difficult ~or developing countries to make 
~·~ptimum use of the potehtial offered by biotechnology. Due to 
their economic underdevelopment, backward industrial structure, 
lack of research capacity and deficient infrastructure developing 
countries will require more time before they can use 
biotechnology on their own. The use of biotechnology by these 
countries is largely dependent on the present and future balance 
of power in the field of biotechnology. There is a high risk of 
developing countries becoming even more dependent on the 
industrialized world. Hence it is extremely important that 
developing countries are given access to biotechn.ol,ogy, so that 
they can decide for themselves whether and how to make use of it. 
Development assistance and cooperation can play an important role 
in this regard. 
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While biotechnology is still at a very early stage of 
development and diffusion it raises numerous extremely important 
questions and issues: What is biotechnology? In which economic 
sectors is it likely to produce major impacts? What is the stage 
of development of biotechnology? Why and how is it so relevant 
for developing countries? What are the conditions that developing 
countries must fulfill to benefit from biotechnological 
development and application? What is the international setting in 
which these developments should be analysed? What are the 
international dimensions that condition its development and 
application in developing countries? What are the economic, 
social and political implications of biotechnological 
development, transfer and application? 
1.2. Definition 
Several definitions of biotechnology have been provided in 
recent years by different institutions and experts. This 
proliferation of definitions is partially the consequence of the 
multidisciplinary character of biotechnology <molecular genetics, 
biochemistry, microbiology and process technology> w~ich reflects 
the difficulties encountered in establishing its boundaries. It 
is also a reflection of the diversity of its scope, including 
agriculture and fisheries, human health care, environmental 
protection, energy, mining and industry. Accordingly, one or 
another definition is adopted in accordance with particular 
interest regarding the purpose of biotechnology development and 
applications. 
Biotechnology alternatively has been defined as; 
the integrated use of biochemistry, microbiology and 
technical sciences with the aim of arriving at the 
technological and industrial applications with the aid of 
micro-organisms, parts of micro-organisms or cells and 
tissues of higher organisms <European Federation of 
Biotechnology>.C2J 
any technique that uses living organisms, or parts of 
organisms, to make or modify products, to improve plants or 
animals, or to deve)op micro-organisms for specific uses 
<European Community and Office of Technology Assessment of 
the US Congress>.C3J 
the application of scientific and engineering principles to 
the process of materials by biological agents to provide 
goods and s~rvices <Organization for Economic Cooperation and 
Development, OECD>. <This definition has been adopted by some 
of the European countri•s.>C4J 
the integrated use of molecular genetics, biochemistry, 
microbiology and process technology with th~-~~~ of supplying 
goods and services, specifically using micro-organisms, parts 
of micro-organisms, or cells and tissue or higher organisms 
<Director-General for International Cooperation, the 
Netherlands>.[5) 
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the application of science engineering to the direct or 
indirect use of living organisms or parts of org•ni~ms or 
products of organisms in their natural or modified forms, for 
the production of goods or the provision of services 
<MOSST>. [ 6 J 
These definitions have one common aspect: they refer to the 
use of micro-organisms and biological agents. But, e•ch of them 
reflect different purposes, or interests and strategies. The 
emphasise however is on the industrial character or relevance of 
biotechnology. Biotechnology tends to be defined as the 
industrial exploitation of biological systems or processes. 
1. 3. Traditional vs. New Biotechnology 
Biotechnology in itself is nothing new. It has been used for 
thousands of years in the manufacture of food and beverages such 
as bread, beer, wine, cheese, soya sauce, and temphe. For 
centuries use has been made of the properties of micro-organisms, 
but without understanding them. The term "biotechnology" dates 
from the time when biological processes came to be understood and 
used consciously. 
Briefly, the evolution of biotechnology can be divided into 
at least four periods. The pre-Pasteur period and the empirical 
practice of selection of animal and plant breeders and 
fermentation for food preservation. This era was characterised by 
the artisanal application of empirical understanding resulting 
from experience alone. It was practical understanding without 
theory or scientific base, technology without science. 
The second period was initiated with Pasteur. Micro-
organisms were identified as the cause of fermentation, followed 
by the discovery of the capacity of enzymes to convert sugar into 
alcohol. This development gave impulse to fermentation technique 
in the food industry. The third period was characterised by 
important technological developments which reduced the impetus of 
biotechnology development in certain areas while giving rise to 
development in other areas • .. 
The last period started with the discovery of the double 
helix structure of DNA in 1953, the first experiments on genetic 
engineering in 1973, and the discovery of the hybridoma technique 
for the making of monoclonal antibodies in the first half of the 
1970s. In the last 20 years biotechnology has taken on a 
revolutionary character due to the development of several 
fundamentally new production techniques: 
1. Fermentation: Production of substances with the.aid of micro-
organisms, e.g. production of beer and antibiotics. 
2. Enzyme technology: Production of substances with the aid of 
enzymes, e.g. the production of several sweeteners. <The 
industrial application of enzyme technology has increased 
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sharply due to the possibility of immobilizing enzymes. This 
involves fixing enzymes on a solid substance <carrier> so that 
the enzymes can be continuously re-used.> 
3. Cell and tissue culture: Cells and tissues of multicellular 
organisms are multiplied outside the organisms <in vitro>. For 
example, whole plants can be produced from plant tissue or a 
single plant cell <regeneration>. 
4. Genetic engineering: A collection of techniques which enable 
the genetic material of a living organism to be modified in a 
manner which goes beyond the natural barriers of mating and 
recombination. In this way new characteristics can be built 
into organisms. The techniques for genetic engineering are 
generally divided into three groups: 
a> Cell fusion: Artificial fusion of cells resulting in new 
combinations of genetic material. Two examples of cell 
fusion are: 
Hybridoma technology: The fusion of an immune cell with a 
cancer cell, resulting in a hybridoma cell. This 
technique is used for producing monoclonal antibodies 
<MAbs>. 
Protoplast fusion: the fusion of protoplasts <somatic 
plant cell whose cell wall has been removed 
enzymatically>. This technique is used in plant breeding. 
b> Recombinant DNA <rDNA> technology: An isolated piece of 
genetic material which is produced, by whatever means, 
outside the cell is inserted into the genome of a host cell 
through 'cutting' and 'splicing' <by means of enzymes>, 
cloning and recombining DNA sequences. 
c> Other forms: These include all other methods of inserting 
genetic material such as micro-injection and macro-
injection, bacterial or viral infection, electroporation, 
etc. 
While the four groups outlined above are mutually supportive 
there is one fundamental difference between them. The first three 
groups as well as traditional biotechnologies were based on the 
empirical or scientific (after Pasteur> understanding of the 
characteristics and behaviour of micro-organisms and the 
deliberate use of the characteristics of each particular organism 
for the achievement of economic objectives. The last group 
manipulates the structural and functional characteristics of 
organisms to overcome their natural limits in performing specific 
tasks that have economic and social interest. The immobilization 
of enzymes and cells and genetic engineering are considered the 
core of "new" biotechnology. 
One of the characteristics of new biotechnology is that it 
is science intensive. In the pre-Pasteur period biotechnology 
involved the application of practical experiences transmitted 
from one generation to another. Even with Pasteur_. and scientific 
knowledge about characteristics of micro-organisms, technological 
application remained basically artisanal. Technological 
innovation arose mainly from the productive sector. The new 
biotechnologies, on the contrary, are science-based. All major 
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innovations and discoveries in new biotechnology have occurred in 
research centres and universities. This aspect, one of the most 
relevant of new biotechnology, has been the subject of debate. So 
has been the initiation of a new technological pattern 
characterised by the increasing association between large 
corporations and universities either directly or through 
intermediate firms.[7J 
~his characteristic poi>es serious challenges for developing 
countries. First, it removes biotechnology research results from 
public access. Second, the linkages between the productive 
sectors and research centres and universities are particularly 
weak in developing countries, if not non-existent. Third, 
research centres and universities in many developing countries 
have the scientific capacity to participate actively in the 
development of new biotechnologies and their application to local 
problems. This, however, requires a change in the science and 
technology policies of these countries for the creation of 
linkages in productive and research and academic centres where 
those links do not exist, or for their strengthening if they 
already exist. 
1. 4. Industrial Bias in Biotechnology 
There is no doubt that biotechnology holds great potential. 
However, most of the work so far appears to focus on the 
industrial-commercial sector at the expense of the agricultural 
sector. <This development tends to be encouraged by government in 
developed countries, including the Canadian government.> This 
reflects the particular problem of industrialised countries. The 
industrialised countries today are confronted with an 
agricultural crisis characterised by growing surpluses of food 
and commodities, which affect prices and increase the burden for 
governments and consumers alike. Any technological innovation 
that increases agricultural production is likely to contribute 
further to this crisis. 
Technological innovation, and in particular, basic or 
radical innovation, play an important role in the industrialised 
countries in shifting fl'"'Om declining industrial sectors to new 
ones which slowly assume the role of dynamic forces behind the 
economic process. An illustration .of this is the shift from the 
steel and coal industry to metallurgy and manufacture of durable 
equipment and finally, to the chemical industry. 
The main purpose of the biotechological programmes of the 
industrialised countries is to avoid a crisis in the chemical and 
petrochemical sectors. In this strategy, biotechnology plays a 
relevant role by creating new products, and new $O~r,ces of raw 
materials, and by reducing the vulnerability of the chemical 
industry, conferring to it a greater flexibility, and reducing 
its capital-intensive character, by the use of methods less 
intensive in the use of energy <in particular hydrocarbons>. It 
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favor& the relocation of the industry and augmenting the value of 
natural resources and of activities either based on the 
production of bulk products of relatively low value added 
<ethanol> or products of very high value added <pharmaceuticals>. 
The fact that the industrial potentialities of biotechnology 
are emphasised, while the agricultural aspects are excluded or 
considered only marginally, is indicative of the fact that 
technological development tends to respond mainly to the specific 
problems of those regions where it originates. 
In developing countries the situation is different. 
Agriculture and food production are the strategic sectors in 
terms of employment and income generation and distribution. The 
role of developing countries, it seems, will be the same as 
traditionally performed, that is, as receivers of equipment, 
know-how, and new products or traditional products obtained by 
new processes. These will allow them to supply the centre with 
raw materials for the new industries which, in turn, will help 
reduce the centre's dependence on some commodities such as 
tropical products, fats and oils, protein <soyabean> and so on. 
Biotechnological developments will have adverse ~ffects on 
developing countries in so far as they result in the reduction of 
international demand for traditional commodities or displaces 
them by new products resulting from biotechnology diffusion. In 
this case, employment, income generation and distribution in 
developing countries will be adversely affected. The crucial 
issues with regards to biotechnology and development thus are: 
What potentialities can biotechnology offer and how can these 
potentialities materialise? What are the conditions to fulfill 
and the barriers to overcome? 
2. IDRC AND BIOTECHNOLOGY 
2.1. General Developments 
Although biotechnolugies are fundamental to many of the 
projects IDRC has supported,(8] the Centre does not have a well 
defined biotechnology policy nor a functional definition for 
biotechnology. Decisions on the use of biotechnological methods 
or tools in development is left to the Program Divisions which 
have the responsibility to determine the appropriateness and 
specific merits of biotechnologies and to recommend whether or 
not projects in this area should be developed. 
There are a number of limitations and consequeQces arising 
out of this lack of a clear policy and functional definition of 
biotechnology, especially in preparing this report. First, there 
are competing but less than clearly formulated definitions 
<ranging from basic bioscience research to applied biotechnology 
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rese•rch to down-stream application infrastructure) which are 
operative across the Divisions. This poses a serious problem for 
coordinating Centre-wide cooperation as well as keeping abreast 
with trends and developments in the area. Second, the parameters 
of the Centre's focus in the area are not easily identified. 
Third, it is difficult to quantify the number of IDRC projects 
and DAPs concerned with biotechnology. Biotechnology, for example 
does not exist as a category in the FAD Management Information 
System <FADMIS>. As a result, there is no easy way to determine 
FAD OAP expenditures in the area of biotechnology. The same holds 
true for other Divisions. Finally, the lack of a functional 
definition makes it difficult to establish the precise nature, 
focus and scope of current divisional planning processes in the 
area. 
The Centre, in addition to formulating a clear policy, needs 
to formulate a functional definition of biotechnology, in 
co~trast to adopting a general/universal definition. The 
multidisciplinary character and the diversity in scope of 
biotechnology make it difficulties to establishing its 
boundaries. A general/universal definition would establish 
boundaries, but it would require ongoing Centre activities in the 
area to comply with such a definition. This not only would lead 
to a great deal of confusion and difficulties, but the fit 
between definition and ongoing activities would be nothing but 
incidental. Accordingly, a definition should be formulated in 
accordance with the particular interest regarding the purpose and 
application of biotechnology in development. 
A functional definition should cover and reflect ongoing 
activities in the area and should be formulated within the 
context of the Centre's mandate. A useful starting point of 
formulating a functional definition would be to divide the area 
into bioscience (basic research>, biotechnology <applied 
research),(9) down-stream industrial-commercial applications of 
biotechnology research methods/products, and application 
infrastructure. 
2.1.1. The 1985 Report on Biotechnology 
The Board of Governors, in light of the above and in 
response to rapid developments in biotechnology research, in 1983 
at the insistence of the then Governor Carl-Goran Heden requested 
the Centre to prepare an introductory policy paper on the state 
of the art of the biotechnologies and their relevance to the 
developing countries. 
The Board felt it should have an opportunity to acquaint 
itself with the subject in order to be able to determine what 
role, if any, IDRC should play·.(10) Specifically, "'ttie following 
issues that were to be discussed: 
Should the Centre depart significantly from the current 
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practice of treating each case on its individual merits or 
should it be more active in soliciting proposals? 
Where should the greater emphasis be; on building research 
capacity or on promoting sound research in countries where 
some capacity already exists? 
If the field was to be narrowed down by determining 
certain "program areas" within which IDRC would respond, 
was this to be done through a multidivisional task force 
or by creating a separate program area? 
According to which criteria might the field be narrowed 
down; by ~ of biotechnology - fermentation, as opposed 
to genetic manipulation; by sector of potential 
application - food, health and agriculture, as opposed to 
industry; by level of research - applied, as opposed to 
basic exploratory work?[llJ 
The Report, "Biotechnology: Opportunities and Constraints," 
p~esented to the Board of Governors in March 1985 identified the 
issues before the Board and the Centre as follows: 
1. A considerable proportion of what is label led "biotechnology" 
has been arrived at empirically. To achieve significant new 
progress in many sectors requires more fundamentaf studies. In 
response, should the Centre devote any of its resources to 
longer term basic research either in Canada or in developing 
countries with a demonstrable competence? Or, should support 
of such research be left to other agencies? 
2. While in general responsive to requests submitted by 
developing countries, a greater or lesser involvement in any 
sector can be encouraged or discouraged. The Centre can be 
active, seeking a leading role as it has in selected areas in 
the past,-Qf"' it can remain passive, awaiting but not 
encouraging project proposals. 
3. Should the Centre foster the establishment of a data base to 
cover information about biotechnology applications relevant to 
developing countries? Or, should the Centre help establish a 
library/information service comparable to those that exist in 
American and European companies and make it available to 
researchers in developing countries? 
4. With reference to sectoral choices the Centre has to decide 
between a few well-c~osen, specialized topics of priority 
interests to developing countries from the variety of 
different sectors of application -- agriculture, medicine, 
sanitation, energy, mining and industry. 
5. In industrial developments the Centre lacks experienced 
expertise in the industrial fermentation sector, in biological 
engineering, in either market research or the marketing of 
manufactured products. At present it is beyond the Centre's 
resources to advise in market research or marketing in any 
branch of industrial fermentation. If however the Centre is 
encouraged to give greater support to industrial' development 
it must consider seriously how to provide the essential 
elements of market research. 
6. In terms of human resources development the time may have 
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arrived for the Centre to focus on assisting government 
planning agencies systematically to assess the present and 
future supply and demands for skills essential in those 
sectors of science and technology to which developing 
countries are given priority, in order to cope with the 
dangers and constraints of biotechnology research and 
development which tends to proceed in an atmosphere of 
secrecy, privatization, industry/university linkages and 
patenting. 
7. Should the Centre concentrate its limited support upon the 
most advanced; those who can conduct applied research and 
exploit its results? Or should the Centre have concern for the 
scientifically less developed and help them over the first 
hurdle towards developing a relevant and realistic science 
policy, and to an assessment of the resources they possess and 
the resources they will need? 
8. Finally, the Cooperative Program might examine in what manner 
' Canadian experience and expertise in the area of biotechnology 
could usefully be made available to the developing world.(12J 
The Board after lengthy discussion: 
1. agreed that, in the field of biotechnology, the Centre 
should give priority to projects of applied research, 
2. invited the President to ensure that there is, within the 
Centre, a focal point for biotechnology which will 
<i> monitor developments; 
(ii> evaluate the needs of the developing countries, 
especially as regards data bases and their 
effective utilization; 
(iii) advise on the type of projects and activities most 
likely to be of benefit to the populations of the 
developing countries, and 
3. invited the President to present a further report on 
biotechnology to the Board in 1987 or 1988.(13] 
2. 1. 2. Recent Developments 
Following the 1985 Board Meeting the Centre continued to 
fund biotechnology related projects but no specific action with 
regards to biotechnology issues raised in the 1985 Report and the 
recommendations of the Board of Governors appeared to have been 
taken. While there is some mention of a "mini-working group 
maintaining a watching brief on biotechnology"[l4] there is no 
evidence of the emergence of a "focal point" at the Centre that: 
monitors developments in the area of biotechnology; ev•luates the 
needs of developing countries in the area; and advises on the 
type of projects and activities most likely to be beneficial to 
developing countries. At the same time, there is ~o.evidence of a 
follow up report on biotechnology having been submitted to the 
Board. The only official Centre activity concerning 
biotechnology, is an annual report to the Minister of State for 
Science and Technology <MOSST>, prepar•d by the Office of the 
9 
Vice-President <Program>, of the Centre'fi total expenditure in 
the area of biotechnology. 
Evidence seems to indicate that the former Vice-President 
<Research Programs>, Joe Hulse, informally retained an overall 
awareness of the Centre's activities in the area of 
biotechnology. He also appeared to have represented the Centre at 
the ICISTR <Interdepartmental Committee on International Science 
and Technology Relations> Sub-Committee on Biotechnology at the 
Department of External Affairs.(15J However, there is no 
indication that with the retirement of the Vice-President in 1987 
that the Centre has maintained it representation on this body. At 
the same time, centre files on biotechnology appear to end around 
1987. 
One of the explanations for the limited action in this area 
appears to have been internal opposition to any specific action 
with regards to biotechnology as indicated in a memorandum from 
AFNS to the Vice President <Research Programs>. The memorandum 
argued that; biotechnology is a non-issue; it should not be a 
central point; AFNS does not plan to support research on 
biotechnology techniques; elevation of this subject m~tter to a 
target for specialized institutes, programs, or divisions, 
whether inside or outside IDRC should be discouraged; if there 
are policies to be set, this can be done with the existing 
divisions and if the general consciousness of the Centre needs to 
be raised, this again will have to be done through the divisions' 
staff; although the Centre should provide leadership in research 
priority setting and in encouraging appropriate ways to conduct 
research, biotechnology is an appropriate subject. On the 
contrary, research driven by a particular technology or 
instrument should continue to be discouraged."(16) 
There appears to have been a recent change in climate with 
regards to biotechnology. This change in climate is due to a 
number of factors of which the most important is the arrival of a 
new Director in AFNS. 
As well, there seems to be a growing awareness of the 
potential as well as of the consequences of biotechnology for the 
developing countries. THere is a growing awareness and need 
expressed for the Centre to keep abreast with developments in 
biotechnology research in order to assess the opportunities as 
well as the constraints of biotechnology for developing 
countries. Information on recent developments in biotechnology 
has been gathered on an individual basis in various divisions 
throughout the Centre. 
Nowhere are these changes more evident than in AFNS. In a 
recent memorandum to the Vice-President <Program) 1 .~FNS raises 
some of the issues of biotechnology and development; its 
potential contribution to development; the danger of increasing 
the North-South gap; ways to ensure that LDC's benefit from 
recent advances; the establishment of mechanisms that encourage 
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biotechnological innovation of relevance to LDC's through 
appropriate reward systems; the limited information on 
developments in biotechnology research and application in 
developing countries at the Centre; and the very limited 
biotechnology expertise of the Centre staff.(17] 
More importantly, at a Centre-wide level, the Office of the 
Vice-President <Program> has built into the Program Committee 
Workplan a seminar process which will have as its first topic 
biotechnology. It is expected that this seminar process will lead 
to a position paper on biotechnology that will be presented to 
the Program and Planning Committee of the Board of Governors. 
2.1.3. Issues 
Some of the key issues raised within the context of 
preparing this report were: The Centre in certain areas of 
biotechnology research is not keeping up with some of the 
developing countries, especially those in Southeast Asia and 
South and Central America: The Centre has little contact with 
biotechnology research in Canada: The Centre has litti~ insight 
into the size of national science and technology/biotechnology 
programs in developing countries and demands for biotechnology: 
There is need for a clearly defined definition and a coherently 
formulated policy of biotechnology: There is a growing need to 
gather up-to-date information on developments in the various 
areas of biotechnology research to assess opportunities and 
consequences, and to provide information and advice for 
developing countries on the possibilities, limitations and 
constraints of biotechnology: There is a need for more risk 
analysis, and analysis of trends in, and socio-economic and 
environmental consequences of biotechnology research, as well as 
more longer-term planning: There is a growing need for more in-
house expertise and education in the area of biotechnology. 
The more immediate questions arising out of these issue are: 
What is the definition and range of biotechnology research issues 
for development? Who is supporting work in this area, and who are 
the users of biotechnology knowledge? How does IDRC itself make 
use of biotechnology re9earch? What developmental trends are 
taking place within the area? What gaps, changing demands and 
opportunities and constraints exist in the field to which IDRC 
must be alert? What policy options must be derived for IDRC in 
terms of future focus, resources, structure and mechanism? 
2.2. Divisional Developments 
2.2. 1. Agricultural, Food and Nutrition Sciences-Division <AFNS> 
1. Current Planning Process 
The Agricultural, Food and Nutrition Sciences Division plans 
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to increase funding for biotechnology projects in order to 
bring these "new tools" to developing countries. Recognizing 
the importance of coming to grips with developments in the 
area AFNS has contracted MTL Biotech <Victoria, B.C.> to 
undertake an in-depth review of Canadian biotechnology 
expertise of relevance to developing countries. The study is 
designed to assist AFNS in the development and application of 
a policy on biotechnology commensurate with the Centre's 
objectives in the Third World. AFNS also is in the second 
phase of a project on Plant Breeders Rights: evaluating 
Canadian patent rights legislation <i.e., gene patenting> and 
its impact on research in Canada, in developing countries, 
and on farmers. Moreover, AFNS is in the planning stage of 
upgrading personnel skill and awareness in the area 
biotechnology, and of formulating strategic positions in 
selec~ed areas of biotechnology research in agriculture. 
2. Initiatives/Discussions 
AFNS has undertaken no initiatives or discussion with the 
Canadian academic/research community or private sector in the 
area of biotechnology outside of ongoing or comp~eted 
projects and DAPs. · 
3. Committees/Reporting Requirements 
AFNS sits on a committee of the Multilateral Affairs Division 
of Agriculture Canada that focuses on plant genetic resources 
development globally. AFNS is under no obligation to report 
on its activities in the area of biotechnology. 
2.2.2. Communications Division <COMM> 
The Communications Division has no current divisional 
planning processes in the area of biotechnology. Moreover, 
the Division has undertaken no discussions or initiatives 
with the Canadian academic/research community or private 
sector with regards to biotechnology. The Communication 
Division is not represented on any committees at the national 
level and has no reporting requirement on activities in the 
area of biotechnology. 
2.2.3. Earth and Engineering Sciences Division <EES> 
1. Current Planning Process 
The focus of the Division is on the urban poor, on making 
better use of local products and local waste,. ~.nd on 
utilizing science and technology in development. Within this 
context, the Division's focus on biotechnology is comparative 
with chemical and mechanical processes. 
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EES is very positive on biotechnology and would like to see 
Centre-wide cooperation in the area, i.e., central 
information gathering to keep abreast of global developments 
in biotechnology research, made available to all divisions. 
The Division's major problems in the area of biotechnology 
are finances and experienced staff. EES lacks expertise in 
biotechnology. A relatively new division EES, in building up 
its manpower requirements, was caught up in the federal 
government's budget cuts. 
EES currently is undertaking a review of its Technology for 
Local Enterprise Program that is to serve as the basis for 
the Division's policy on science and technology, and 
ultimately its biotechnology policy. Moreover, an 
understanding in principle has been reached with AFNS to 
develop a joint sub-program on Post Production Systems <PPS> 
with a focus on biotechnology. 
2. Initiatives/Discussions 
There are no initiatives or discussions with the Canadian 
academic/research community or private sector with regards to 
biotechnology. 
3. Committees/Reporting Requirements 
The Division is not participating in any committees at the 
national level and has no requirement to report on activities 
in the area of biotechnology. 
2.2.4. Fellowships and Awards Division <FAD> 
1. Current Planning Process 
Fellowships and Awards does formal and informal training in 
biotechnology related fields. While FAD focuses on science 
and technology, there is no special focus nor a divisional 
planning process for the area of biotechnology. FAD training 
activities are mainly in response to requests from other 
Centre divisions. \ 
2. Initiatives/Discussions 
FAD has undertaken no discussions or initiatives with the 
Canadian academic/research community or private sector with 
regards to biotechnology. 
3. Committees/Reporting Requirements 
The Division is not participating in any committees at the 
national level and has no requirement to report on activities 
in the area of biotechnology. 
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2.2.5. Health Sciences Division <HS> 
1. Current Planning Process 
The Health Sciences Division views biotechnology as a tool to 
aid development in certain instances and will use 
biotechnological tools in projects where they are 
appropriate. To date 10-157. of HS support is invested in the 
use of biotechnological methods. Hs·s focus on biotechnology 
is primarily in the area of diagnostics and contraceptives. 
While biotechnology tools may be used more frequently in the 
future, there is no special focus in the area of 
biotechnology at HS. The focus of HS is to build capacity in 
the health sciences in developing countries to the benefit of 
the poor. Its primary focus is on getting existing solutions 
to the problems. The feeling is, there are not that many 
outstanding problems in the field of human health care that 
call for new biotechnological solutions. 
HS supports very little development of biotechnological 
capacity in developing countries. For the moment,.'HS is not 
con~idering proposals for biotechnology development in 
developing countries. The Division is interested in 
determining more clearly the benefits of biotechnology for 
the poor in the field of health care. Within the Centre, 
there are discussions underway for closer cooperation with 
AFNS in area of biotechnology in pest control. 
2. Initiatives/Discussions 
While there are no specific initiatives or discussions in the 
area of biotechnology, HS has ongoing discussions with the 
Canadian academic/research community and the private sector 
<e.g., with Connaught Laboratories in the area of 
vaccineology and diagnostics>. 
3. Committees/Reporting Requirements 
The Division is not participating in any committees at the 
national level and Aas no requirement to report on activities 
in the area of biotechnology. 
2.2.6. Information Sciences Division <IS> 
1. Current Planning Process 
Information Sciences has no specific planning process in the 
area of biotechnology. The Division is currently formulating 
a strategy for the 1990s in the larger area of science and 
technology. Within this context biotechnology is viewed as an 
important aspect of development. The focus is on improvements 
in the flow of information from source to use in order to 
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give researchers, policy-makers, and practitioners in 
developing countries access to scientific and technical 
information and information technologies. 
The major thrust of the Division is to link the scientific 
communities in developing countries, and to link them to the 
"invisible college" of the scientific community of the 
developed countries. Within this context IS is looking at the 
possibility of regional networks in biotechnology. 
2. Initiatives/Discussions 
IS has undertaken no initiatives or discussions with the 
Canadian academic/research community or private sector with 
regards to biotechnology. 
3~ Committees/Reporting Requirements 
The Division is not participating in any committees at the 
national level and has no requirement to report on activities 
in the area of biotechnology. 
2.2.7. Social Sciences Division <SSD> 
1. Current Planning Process 
Currently, there is no special focus on biotechnology in the 
Division. However, SSD has a keen interest in ethics and risk 
analyses in the area of biotechnology and development. It 
regards these issues as crucial and in need of serious 
attention. 
The Division has an ongoing project that looks at 
biotechnology within the larger framework of science and 
technology in development. "Technology Perspectives <Latin 
American>" looks at issues of new technologies in development 
in order to formulate a long-term scientific and 
technological strategy for the region. Phase II of the 
project focuses on tdentifying existing scientific and 
technological capabilities, the main trends of current 
technological change, and feasible socio-economic, political 
and technological strategies for countries in the region to 
use creatively to incorporate the new wave of technological 
innovations, including biotechnology. 
Moreover, the Division is holding talks with AFNS on 
cooperation in the area of socio-economic consequences of 
biotechnology in agriculture, i.e., socio-economic: 
consequences of the introduction of new and improved crops 




2. Ini tiatives/Oiscussions 
SSD has undertaken no discussions or initiatives with the 
Canadian academic/research community or private sector with 
regards to biotechnology. 
3. Committees/Reporting Requirements 
The Division is not represented on any committees at the 
national level and has no requirement to report on activities 
in the area of biotechnology. 
3. CANADIAN INITIATIVES IN BIOTECHNOLOGY[18J 
3.,1. Developments at the Federal Level 
Canada, as most other developed countries, recognizes 
biotechnology as a priority for research and development leading 
to new opportunities for future industrial growth. I~·1980, the 
Ministry of State for Science and Technology <MOSST> ·established 
a Task Force on Biotechnology to advise the Minister on 
development o~ an effective Canadian strategy for promotion of 
biotechnology. The task force recommended a long-term federal 
funding commitment, industry stimulation through tax incentives 
and technology transfer from government and university 
laboratories, and increased financial support to the Medical and 
National Research Councils <MRC and NRC> for interdisciplinary 
research, development and training.[19] Priority research areas 
were identified in nitrogen fixation, plant strain development, 
human and animal health care products, mineral leaching and 
metals recovery, forestry and forest products, waste treatment, 
and fisheries/marine aquaculture. 
This National Biotechnology Strategy was adopted in 1983 by 
the federal government. The Strategy is administered by the 
Technology Policy Branch of the new Department of Industry, 
Science and Technology Canada <ISTC>. Also in 1983, a National 
Biotechnology Advisory Committee, comprised of government, 
industry and university representatives, was established to 
advise the Minister on new developments and policy requirements 
in biotechnology. The Advisory Committee's annual reports are 
published by ISTC. A federal Interdepartmental Committee on 
Biotechnology <lCB> was established, chaired by ISTC, to review 
proposed federal government activities and monitor progress under 
the new National Biotechnology Strategy. 
Significant activities have included establi~h,ment of 
Biotechnology Networks to promote communication among researchers 
in each of the priority research areas. Each Network is 
administered by a federal department and membership is open to 
anyone interested in the development and application of 
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biotechnology in a particular sector (for a listing of the 
Networks see Appendix C>. 
Moreover, the government implemented a Biotechnology 
Development Program administered by the National Research Council 
through the Industrial Research Assistance Program <IRAP>. Under 
the Program, which is designed to encourage technology transfer 
to the industrial sector, companies are eligible for financial 
support providing they are accessing technology developed in 
universities, federal laboratories or Provincial Research 
Organizations. Technology transfer through international 
collaboration may also be funded. 
By the end of the 1987-88 fiscal year, the Programme has 
supported 81 projects involving 63 biotechnology companies in 
collaboration with 22 universities and two provincial research 
organizations. The total value of the R&O projects funded between 
1983, when the programme was launched, to the end of 1987-88, was 
$42.6 million, with the Federal Government contributing 57'l. 
($24.4 million>. Of the 81 projects 31 were in health which 
received 39'l. of the expenditure; 24 were in agriculture with 27/. 
of total expenditure; food 13 <ll'l.>; cellulose/waste,S (9'l.>; 
mining 2 <7'l.>; and 6 others <7'l.>. 
The federal government also strengthened its biotechnology 
research capacity. It established two new research institutes 
under the auspices of NRC: The Biotechnology Research Institute 
<BRI> in Montreal, which focuses on industrial biotechnology, on 
medical and pharmaceuticals and on genetic engineering; and the 
Plant Biotechnology Institute <PBI> in Saskatoon, which assists 
private sector companies with biotechnology development involving 
plant cell technology and plant genetic engineering. 
Agriculture Canada has expanded its activities in plant, 
animal and food biotechnology. Other federal departments such as 
Health and Welfare, Energy, Mines and Resources, and Fisheries 
and Oceans have their own biotechnology programs and the federal 
granting councils provide support for research carried out at 
Canadian universities. Finally, the department of External 
Affairs, through the Interdepartmental Committee on International 
Science and Technology Relations <ICISTR> Sub-committee on 
Biotechnology, provides a forum for the coordination of federal 
efforts in biotechnology with the international community in this 
field. 
3.2. Federal Regulatory Framework 
Current legislation applicable to biotechnology in Canada 
pertains to specific product categories, without regard to the 
process of production. These product categories include 
veterinary biologics, pest control products, foods, drugs, 
cosmetics and medical devices. Other products intended for 
environmental use, such as waste treatment of mineral leaching, 
17 
or waste products unintentionally released to the environment, 
are addres5ed by the Canadian Environmental Protection Act 
<CEPA>. Research activities without a clearly defined end product 
can be regulated under CEPA. 
Canadian guidelines for handling recombinant DNA, animal 
viruses and cells were developed in 1977 by the Medical Research 
Council.[20J The guidelines specify appropriate levels of . 
containment for micro-organisms, including viruses, according to 
the toxin, the degree of pathogenicity, and the nature of the 
research. They were revised in 1979, and again in 1980, with 
progressive relaxation justified by continued safe experience and 
consistent with international views.[21J MRC guidelines clearly 
apply to laboratory research <culture quantities up to lOL> and 
are not intended to address procedures for field trials or open 
environmental release. Notification of MRC is required only in 
MRC funding applications. Guidelines are not enforced by MRC, 
except by withholding of funds. 
The major federal statutes applicable to products of 
biotechnology are administered by Health and Welfare Canada, 
Agriculture Canada and Environment Canada.[22J The pr~vinces and 
territories play a prominent role in regulation, sharing 
responsibility with the federal government for environmental 
protection, and having primary responsibility for occupational 
health. Occupational health legislation is the only type of 
regulatory instrument that could be used at present for control 
of research activities. Most research activities adhere closely 
to MRC guidelines, although the guidelines are voluntary. 
Provincial environmental legislation is generally modeled after 
federal instruments, and usually lacks pre-manufacture 
notification requirements, or specific penalties for violation. 
Applicability to biotechnology products or wastes is uncertain, 
and may vary from province to province. 
In 1985, the Interdepartmental Committee set up a Sub-Group 
on Safety and Regulation, co-chaired by Health and Welfare Canada 
and Environment Canada, to examine safety and regulatory issues 
in biotechnology, and advise on the adequacy of the regulatory 
system if required. In addition, the federal government has 
started a consultative process with the provinces to arrive at a 
coordinated national approach to biotechnology regulation. 
Individual federal agencies are also reviewing regulatory 
pcsitions, instruments and responses in order that they w111 be 
able to deal effectively with new technological developments. The 
Medical Research Council has established a subcommittee, jointly 
with Health and Welfare, reporting to the MRC's Standing 
Committee on Ethics in Experimentation for review of MRC 
Guidelines with respect to new developments in bjo~~chnology. 
National Health and Welfare has established a Biotechnology 
Committee within the Health Protection Branch to examine all 
aspects of biotechnology that impinge on Branch activities, 
including reviews of federal health protection legislation. 
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Agriculture Canada has identified the need for an advisory 
panel on biotechnology to review regulatory responses related to 
veterinary biologics. Environment Canada, in conjunction with the 
Department of National Health and Welfare, administers the new 
Canadian Environmental Protection Act <CEPA> which was passed in 
June 1988. CEPA subsumes the old Environmental Contaminants Act 
which was remedial rather than preventative in approach and 
precluded regulation of living organisms. The definition of a 
substance under CEPA, 'any distinguishable kind of organic or 
inorganic matter, whether animate or inanimate .•• ·, is 
sufficiently broad to include products of biotechnology. CEPA is 
covering safety in the research, production, use and disposal of 
products. Pre-manufacture notification is required under this 
Act. 
Provincial agencies are also in the process of reviewing 
their regulatory positions pertaining to biotechnology. For 
example, Ontario and Alberta have established interdepartmental 
committees to study their respective regulatory regimes and 
Manitoba is actively consulting with industry. The provinces are 
supportive of consistent national action and look to ~he federal 
government to provide scientific information and criteria to aid 
in setting policies 
Canada has also been very active in the OECD work on safety 
and regulations, and is supportive of the OECD proposals for the 
international harmonization of regulations related to 
biotechnology.(23) A joint Canada/DECO workshop on biotechnology, 
held in Toronto in April 1987, highlighted the importance of 
public confidence in the regulation of biotechnology, and 
supported the creation of an international data base for 
regulatory and risk assessment criteria and information. 
3. 3. Canadian Biotechnology Industry 
According to the government's 1988 Can•dian Biotechnology 
Industry Sourcebook, the number of commercial companies actively 
involved in researching or using biotechnology research in Canada 
had grown from 110 in 1906 to 218 by 1988. Companies actively 
involved in biotechnology are concentrated in the health care 
sector followed by agriculture and waste treatment. 
The majority of companies indicated that application of 
their biotechnology activities are pertinent to multiple sectors. 
However, in the health care sector 494 of the reporting companies 
claim applications for research unique to their sector; in 
agriculture the similar figure is 274; for all others 
<aquaculture, chemicals and alternative energy; mineral 
resources; food and beverages; forestry and forest products; 
waste treatment> less than 20/. of the companies involved have 
applications which are unique to one sector. 
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On the ba~is of confidentiAl as well as published 
information provided by 173 companies, there Are 1478 persons 
involved in biotechnology and 174 companies reported R&D 
expenditure to be approximately Sl64 million. There are estimated 
to be almost 1850 persons involved in biotechnology in Canada and 
annual expenditures for R&D are approximately S200 million or 
double the figure of 2 years ago. There has been an obvious 
growth in terms of expenditures and numbers of personnel involved 
in biotechnology since the release of the 1986 sourcebook: 
indeed, the number of companies involved in biotechnology R&D 
between 1986 and April 1988 has increased 16'l..[24J 
4. DONOR AGENCIES ANO INTERNATIONAL INSTITUTIONAL 
INITIATIVES[25J 
In the process of establishing a special programme on 
"Biotechnology and Development Cooperation" the Directorate-
General for International Cooperation <DGIS> of the Netherlands 
in 1988 carried out an inventory study of biotechnology policy 
and activities of donor agencies and organizations. fhe study 
surveyed seven <7> donor country agencies, the Rockefeller 
Foundation and the European Community, thirteen <13> United 
Nation agencies, the World Bank and three <3> regional 
development bank as well as thirteen member institutes of the 
Consultative Group on International Agricultural Research 
<CGIAR).[26J 
An examination was also made the sectors where biotechnology 
was primarily used <agriculture and fisheries, human health care, 
environmental protection, energy, mining and industry> and the 
type of activities <technological research, training and 
education, physical capacity-building, socio-economic studies, 
information supply and advisory services>. 
The biotechnology policy of the different organizations 
varies widely. While some organizations already have a 
biotechnology programme for the benefit of developing countries, 
others still devote hardly any?attention to biotechnology. The 
most active organizations include USAID, the Rockefeller 
Foundation, the UN agencies ILO, UNESCO, UNEP and UNIDO, and many 
of the IARCS <International Agricultural Research Centres> of the 
CGIAR. Many donors <e.g., ODA, DANIDS, SAREC, CIDA, EC, IAEA, 
UNCSTD~ UNCTAD, WFP, WHO, WIPO, AfDE, ADB and IDB> do not devote 
any special attention to biotechnology and developing countries. 
There are indications that several donors like ATSAF, DGIS, FAD, 
IFAD, UNDP and WB are currently formulating a biotechnology 
policy for the Third World. There is no internation•l 
coordination at present. 
Most of the organizations which are active in the field of 
biotechnology have technological research projects, notably in 
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agriculture <arable farming and animal production>, human health 
care and industry. Few research activities were reported in the 
environmental protection sector, and no activities in the energy 
and mining sectors. In addition to technological research, a 
great deal of attention is devoted to training and education. 
Especially UN agencies undertake activities in the field of 
socio-economic studies, information supply and advisory services. 
4. 1. National Donor Agencies 
At present only USAID and the Rockefeller Foundation have a 
special programme on biotechnology for developing countries. 
USAID has an extensive biotechnology programme in which the 
development and application of biotechnology as well as the 
building up of national research capacity in developing countries 
are priorities. USAID has recently formed a Standing Committee on 
Biotechnology to provide advice on the technical, regulatory and 
programmatic issues surrounding biotechnology and to develop 
mechanisms to address these issues. The Committee serves as 
liaison with other US agencies more substantially involved in 
supporting and regulating biotechnology. 
The Rockefeller Foundation in 1984 set up a special 
biotechnology programme in the framework of its science and 
technology policy. The goals of the programme are: to assure that 
new techniques of crop genetic improvements based on advances in 
molecular and cellular biology are developed for rice; to 
facilitate the transfer of these biotechnologies to rice breeding 
programmes in the developing world for use in producing improved 
varieties that address priority needs; and to help build the 
scientific research capacity necessary for continued development 
and application of new rice genetic improvement technologies in 
selected developing countries. 
Other donor agencies such as ATSAF <Federal Republic of 
Germany> and DGIS <The Netherlands> are holding consultations on 
the possibility of setting up such a programme. The other donors 
do not yet have any plans to draw up a definite policy on 
biotechnology for the Third World. Several of them, ODA <United 
Kingdom>, SAREC <Sweden>' and European Commission do, however, 
have activities in this area. 
Most biotechnology activities are concerned with the 
agricultural sector and involve technological research and the 
following subjects: <1> plant cultivation and improvement <tissue 
culture and genetic engineering>; <2> BNF by means of Rhizobium; 
<3> diagnosis of animal and plant diseases <MAb test and DNA 
probes>; and <4> animal nutrition Cbioconversion of agro-
industrial and agricultural waste>. There are als9 ?everal 
technological research projects in the human health care sector. 
These generally involve diagnosis <MAb tests or DNA probes) of 
diseases such as diarrhea and malaria. In addition to 
technological research, a great deal of attention is devoted to 
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training and education in the field of biotechnology. 
4.2. UN Agencies 
The extent to which attention is devoted to biotechnology 
for developing countries varies widely between the different UN 
agencies. Agencies such as ILO, UNESCO, UNEP and UNIDO already 
have extensive biotechnology programmes. 
ILO is actively and continuously monitoring the socio-
economic effects of the advanced biotechnologies with the aim of: 
<a> determining the socio-economic impact of introducing specific 
biotechnologies designed to improve the production of major food 
and cash crops; <b> assessing the capacity of existing extension 
structures to disseminate new biotechnologies to small farmers; 
<c> improving understanding of structural changes in rural 
employment induced by the biotechnology revolution. The ILo·s 
approach is to identify policies and measures, at both national 
and international level, in order to promote biotechnology·s 
potential for helping the poor in developing countries, and to 
rectify negative developments. ILO also has a focus o~ workers' 
safety and occupational health. 
UNESCO has been active in the field of biotechnology for a 
long time. Its focus is on the formulation of policies and the 
development and strengthening of infrastructure in the field of 
biotechnology. It has emphasized the need for elaborating 
national policies for research in biotechnology and its 
application. This has resulted in the establishment of: <1> 
Global network of Microbiological Resources Centres <MIRCENs> in 
collaboration with UNEP and the International Cell Research 
Organization <ICRO> in 1974. The primary focus of the MIRCENs is 
to enhance the quality of human environment and the life of the 
humans in the developing areas of Asia, Africa, and Latin America 
by bringing into play the full potential utility of micro-
organisms; <2> Regional Programme of Biotechnology for Latin 
America and the Caribbean in collaboration with UNIDO and UNDP 
<1987-1991>. This programme promotes collaborative applied and 
basic research, training, and development of biotechnologies and 
products, and their indu'strial application and commercialization. 
The programme also aims at mobilizing financial and technical 
support from developed countries for this purpose. The programme 
is divided into two subprogrammes: ·basic development of 
biotechnologies and products' and •technological development and 
industrial application of biotechnology·. UNESCO is responsible 
for the first subprogramme which involves activities regarding 
laboratory R&D and training of human resources in b•sic 
scientific disciplines of biotechnology to support scientific-
technological developments. UNIDO is responsible. fo~ the second 
subprogramme. 
UNEP has been active in the field of biotechnology since the 
1970s. It has gradually expanded its activities in the fildd of·· 
;:-_applied microbiology and biotechn'ology. The central objective is 
the use of these technologies for environmental protection in 
developing countries and for the conservation of biological 
diversity. UNEP is currently involved in a large number of 
biotechnology activities, either on its own or in collaboration 
with other organizations. The projects mainly involve 
technological research and training. 
UNIDO has an elaborate biotechnology policy for the benefit 
of developing countries. Its major goal is the development of 
national capacity-building in developing countries and to solve 
some of the constraints and problems faced by the developing 
countries in their biotechnology efforts. UNIDO has established 
two specific biotechnology programmes: <1> International Centre 
for Genetic Engineering and Biotechnology <ICGEB>. ICGEB, 
established in 1983, is divided into two centres, one located in 
Triest, Italy and one in New Delhi, India. The centre in New 
D•lhi concentrates on agriculture and health. The Italian half of 
ICGEB focuses on industrial microbiology. Training of scientific 
and technological personnel from developing countries represents 
a key element in ICGEB's activities. In addition ICGEB if the 
focal point in a network of affiliate regional and na~ional 
research and development institutes, where work of special 
interest wi 11 be carried out; <2> Regional Programme of 
Biotechnology for Latin America and the Caribbean in 
collaboration with UNESCO and UNDP <1987-1981>. UNIDO, as 
mentioned above, is responsible for the second subprogrammes, 
'technological development and industrial application of 
biotechnology·, which involves projects regarding the invention 
and evaluation of technologies and the upgrading of human 
resources for industrial application of biotechnologies. 
Others UN agencies do not yet have any plans to formulate a 
policy on biotechnology. Several of them <IAEA, WHO, and WIPO> 
do, however, have many activities in this field. FAO, IFAD and 
UNDP are currently formulating a specific biotechnology policy or 
intend to do so in the near future. 
Most biotechnology activities involve the sectors 
agriculture, human health care and industry. Technological 
research projects in the agricultural sector mainly focus on the 
following fields: <1> plant cultivation and improvement <ti~sue 
culture and genetic engineering>; <2> BNF by means of Rhizobium; 
<3> biological control of pests <Bacillus thuringiensis and 
genetic sexing of insects>; (4) animal health care by means of 
development and production of diagnostic tests <MAb tests and DNA 
probes> and vaccines <rDNA technology>; <5> animal breeding <ET>; 
and <6> improvement of animal nutrition <bioconversion of agro-
industrial and agricultural waste>. In the human health care 
sector, the emphasis is on the development and pr_p~~ction of 
diagnostic <MAb tests and DNA probes> and vaccines <rDNA 
technology>. There are few research projects in the field of 
environmental protection, and no research activities were 
reported in the energy and mining sectors. 
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The nature of the activities varies widely. In addition to 
technological research, Attention is devoted to training and 
education, physical capacity-building, socio-economic studies, 
information supply, and advisory services. It should be mentioned 
that UNIDO is the only UN agency which publishes a 
biotechnological research monitor regularly with the objective to 
sensitize scientists and policy-makers. 
4.3. Development Banks 
The approach taken by the development banks is more or less 
the same. At present none of the banks mentioned has a 
biotechnology policy, but they do not rule out the possibility of 
formulating one in the future. The World Bank has already taken 
concrete steps in this direction. 
The World Bank is currently sponsoring a study of the 
application of biotechnology in developing countries, with a view 
to determining how the Bank should invest in biotechnology and 
for what purpose. The aim of the study is to identify the 
opportunities and constraints for the application of 
biotechnology in developing countries, and to develop' a strategy 
for public sector investments in biotechnology of relevance to 
national agricultural research systems <NARSs> and development 
agencies. <The study is being co-financed by the World Bank and 
the Australian Government, and is being undertaken jointly by the 
World Bank, the Australian Centre for International Agricultural 
Research <ACIAR>, and the International Service for National 
Agricultural Research <ISNAR>.> 
Biotechnology activities are mainly conducted in the 
agricultural sector <arable farming>. Virtually no activities 
were reported in human health care, environmental protection, 
energy, mining and industry. Attention is mainly devoted to 
training and physical capacity-building. 
4. 4_. __ C_o_n_s_u_l _t_a_t_i_v_e_G_r_o_u"'""'p'--_o_n __ I..:..n..:..t_e-'--r-'-n_a_t..:....:..i_o_n_a_l_A_g,,,,_r_i_c_u_l_t_u_r_a_l __ R_e_»_e_a_r_c_h_ 
<CGIAR> 
CGIAR has recently adopted a provisional biotechnology 
policy which recommends that biotechnology research of the 
Centres should be geared to solving problems and not to the 
development of new techniques. Besides, more strategic <up-
stream> research should be acquired from highly specialized 
institutes and universities. Moreover, cooperation with the 
private sector is considered important. <It should be mentioned 
that the Director of AFNS, Geoffrey Hawtin, is a member of a 
CGIAR task force on biotechnology chaired by The ~e~herlands, 
which is concerned with legal and policy issues.> 
All technological research institutes of the CGIAR mentioned 
make use of biotechnology. The IARC's biotechnology activities 
24 
all lie in the agricultural sector, of course, notably in the 
field of tissue culture and disease diagnosis <MAb tests and DNA 
probes>. The institute which is most active in the field of rDNA 
technology <vaccine development> is ILRAD. Other institutes such 
as IBPGR, ICRISAT, IITA, LICAT and IRRI also make use of rDNA 
techniques; this often involves gene mapping. In addition to 
technological research, a great deal of attention is devoted to 
training. Occasionally, socio-economic studies are carried out, 
although specifically recommended by TAC. No reply was received 
from "Centro Internacional de la Papa" <CIP>. 
5. TRENDS AND ISSUES 
Biotechnology, because of its nature and its potential, 
trends in biotechnology research, and the issues arising from 
them requires special consideration beyond the more general 
framework of science and technology. There are obvious short-term 
considerations arising out of the nature of biotechnology, its 
opportunities and constraints for development, and tr~nds in 
biotechnology research. Then, there are more fundamental and 
longer-term considerations arising out of the potential of 
biotechnology with regards to globally sustainable development 
and global environmental concerns. 
Biotechnology could put an end to famine and diseases, solve 
problems of waste disposal, deforestation, and high energy costs. 
Further, biotechnology is readily adapted to the specific 
conditions prevailing in developing countries. Its applications 
are often uncomplicated and non-capital intensive and do not 
usually require much energy. 
But, biotechnology may also have predominantly negative 
socio-economic consequences for developing countries <e.g. 
substitution of raw materials, industrialization of agriculture 
and technology privatization> which are compounded by their 
economic weakness and limited legislation. 
Its nature <basic l"esearch in biotechnology is science-
intensive) and trends in biotechnology research <privatization 
and an industrial-commercial bias in research, and patenting and 
restricted access to processes and products> will make it 
difficult for developing countries to make optimum use of the 
potential offered by biotechnology. The us~ of biotechnology in 
developing countries is largely dependent on the present and 
future balance of power in the area. There is a high risk of 
developing countries becoming even more dependent on the 
industrialized countries. 
In light of the nature and the extent of the possible 
effects of biotechnology on developing countries one cannot but 
concur with the view of the Report by The Netherlands' Directore-
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General for International Cooperation on "Biotechnology and 
Development Cooperation":(27J Biotechnology, its research, 
application and consequences should not be neglected by those 
responsible for development cooperation. Donor countries and 
organizations, should consider developing a specific policy on 
biotechnology and development. The important issues are; how to 
secure access of developing countries to biotechnological 
knowledge and technology; how to use biotechnological 
technologies to assist in solving critical problems in developing 
countries; and how to minimize the negative effects of 
biotechnology on developing countries. 
In addition, more attention should be devoted to socio-
economic analyses, technological assessment, risk assessment 
regarding environmental release of genetically engineered 
organisms in developing countries. Attention should focus on the 
need for information supply on current biotechnological 
deyelopments directed towards policy~akers, development workers 
and-~esearchers in both developed and developing countries. 
Moreover, there is a need for greater coordination and 
cooperation of donor agencies and organizations with the aim of 
establishing joint programmes on specific issues in b~otechnology 
and development. 
The challenge to donor agencies and organizations and the 
developing countries is to devise innovative mechanisms to 
facilitate the transfer of technology from the private sector in 
industrialized countries to both the public and the private 
sec±or in the Third World under mutually beneficial arrangements. 
The challenge for IDRC, if it is to be a serious player in 
biotechnology and development, is to keep abreast with trends and 
developments in biotechnology research. The Centre has to be more 
actively involved in gathering information in a systematic manner 
on international developments in the area of application of 
biotechnology in Third World countries. 
The Centre needs to focus more on longer-term socio-economic 
and environmental impact and risk analyses with regard to the 
opportunities, constraints and consequences of biotechnology on 
developing countries. The Centre must facilitate more actively 
the North-South and South-South information flow in the area of 
biotechnology. The Centre further needs to consider expanding its 
role to advise developing countries on appropriate 
biotechnologies for development. 
In order to take on this mandate the Centre needs: critical 
in-house scientific expertise to monitor, choose and utilize new 
products and processes and adapt them to the real limiting 
factors in developing countries; skills to acquir~ ~ew 
technologies from the public or private sector in industrialized 
countries, under mutually suitable licensing and/or royalty 
arrangements for the benefit of developing countries; the 
capacity to integrate new technologies into existing R~D 
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programs; and the skills to identify and develop well-chosen and 
effective collaborative research programs with public and private 
sector laboratories in developed and developing countries. 
Beyond the obvious short-term considerations there are more 
fundamental longer-term issues arising out of the potential of 
biotechnology within the context of globally sustainable 
development and global environmental protection.(28J 
Given the present direction of industrial development, it is 
anticipated that as we approach the 21st century, humankind will 
be confronted with an increase in environmental problems on a 
global scale, the exhaustion of available natural resources, and 
the need to conquer incurable diseases, a rise in the incidence 
of stress due to a highly scientific and technological society, a 
growth in population, the advent of an aging society and so on. 
Extending the existing boundaries of science and technology 
wrll not be sufficient to solve these problems. It will be 
necessary to make new efforts to build up new modes of science 
and technology and models of development in harmony with nature 
and human society and to carry out fundamental reform of existing 
science and technology and development pattern. · 
The elucidation of the superior biological functions 
<through bioscience/biotechnology research> will contribute to 
the development of science and technology in harmony with nature 
and human society. It could be the seeds for the development of 
future science and technology, the promotion of which from a 
long-term viewpoint will be significant. 
Existing science and technology are large scale and are 
based on high temperature, pressure and speed and are high in 
energy consumption. Bioscience/biotechnology research could 
possibly result in the fundamental reform of existing science and 
technology making it kinder to human beings in such a way that it 
will be distinguished for its saving of energy and resources and 
lack of pollution in harmony with the natural environment and 
human society. 
Securing food and forestry resources and conquering 
incurable diseases are problems which are common to many Third 
World and other countries. The elucidation of the superior 
biological functions should produce sufficient basic answers to 
enable these various problems to be dealt with and eventually to 
be overcome. 
Without a question, it is mainly the deeply rooted 
traditional industrial development pattern and underlying value 
structure of the developed countries that has led to the growing 
destruction of our natural habitat. However, th1s·d~structive 
structure and pattern of socio-economic interaction and its 
governing value structure are not easily transformed. Thus, the 
question has to be; to what extent do our hopes lie with 
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developing countries adopting a more beneficial pattern of social 
and economic development? Of developing countries taking the lead 
in spearheading development more in harmony with nature and human 
society? 
The challenge for donor agencies and organizations is to 
encourage, assist and facilitate an alternative development in 
the Third World, not only for the benefit of the poorest of the 
poor but for the benefit of all of humankind. Given their 
specific location, they are in a unique position to critically 
influence future global developments. With their global 
connections in the development community, the academic and 
research communities in both developed and developing countries, 
donor agencies and organizations such as IDRC are in a position 
not only to formulate a bold new vision of global development 
that must start with the developing countries, but to shape and 
influence the necessary rethinking and debate in the global 
community. 
In order to take up this challenge donor agencies and 
organizations need to rethink and reconceptualise traditional 
views of development. They need to focus beyond the narrow 
confines of locally sustainable development and local 
environmental protection on globally sustainable development and 
global environmental protection. Further, they need to refocus 
from the limited focal point ·of the poorest of the poor in the 
Third World to poverty and environmental destruction on a global 
sea 1 e. 
IDRC, given its broadly defined legislative mandate,[29J is 
in a unique position, within the context of formulating a 
position on biotechnology, to take the lead in rethinking and 
reconceptualising development and in encouraging, assisting and 
facilitating the start of an alternative development in the Third 
World. 
Some of the fundamental questions for the Centre within this 
context will be; what model of development does the Centre 
currently support and what are the consequences of this kind 
development for the rural poor, developing countries, and 
globally? What type of ~evelopment should the Centre support and 
encourage in the Third World? 
6. RECOMMENDATIONS . 
In view of the nature and extent of the possible effects of 
biotechnology on developing countries and in light of the 
observations and findings of this Report the following 
recommendations are made: 
The Centre, within the context of its traditional 
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activities, should: 
1. Adopt a clear policy and an operational definition of 
biotechnology. 
2. Implement the 1985 Board decisions on biotechnology. 
3. Resume its role in the ICISTR Sub-Committee on 
Biotechnology <External Affairs>. 
4. Upgrade Centre personnel skill and awareness in the 
area of biotechnology. 
5. Gather, in a more systematic and institutionalized way, 
up-to-date information to assess opportunities and 
constraints of developments in the various areas of 
biotechnology research for developing countries. 
Going beyond its traditional activities the Centre, within 
its broadly defined legislative mandate, should: 
6. Develop in house capabilities and focus on ~cnger-term 
socio-economic and environmental impact and risk 
analyses with regard to the opportunities and 
constraints of biotechnology for developing countries. 
7. Expand its role, in cooperation with other donor 
agencies and organizations, to advise developing 
countries on appropriate biotechnologies for 
development. 
8. Rethink and reconceptualize, within the context of 
formulating a position on biotechnology in development, 
its traditional view of development; expand its focus 
beyond the narrow confines of locally sustainable 
development and local environmental protection to 
globally sustainable development and global 
environmental protection; and expand the focus from the 
poorest of the poor within their setting of the Third 
World to a focus on their conditions within the larger 
global socio-economic and environmental context. 
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INTERNATIONAL DEVELOPMENT RESEARCH CENTRE APPENDIX A 
CENTRE DE R.ECllERalES POUR. LE OavELoPPEMENT INTER.NATIONAL 
MEMORANDUM/NOTE DE SERVICE 
DAlf August 1989 
Review of' DB! .Activities in the Area of Biotechnology 
Based on discussions with Geoffrey Bawtin, I have revised 
t.he terms of reference for the proposed ooosultancy on 
biotechnology "1.i.ch are outlined below;· 
1. Review existing C'kntre files and policy docunents I 
related to biotechnology and provide an overview of the 
ma.in issues that have emerged and diSC11SSioos that have 
taken place to date within~ on this subject. 
2. Using the Centre's information systems, prepare a table t 
of all IDP.C projects and DAPs {ongoing a.."ld completed)· 
cxmcerni.ng biotechnology_. 
3. Based on discussions with relevant Divisions, prepare a 
sumnary of any current divisional planning processes in 
the area of biotechnology. 
4. Review Canadian Government initiatives in the field of 
biotechnology and indicate any requirements that the 
Centre may have to report on our activities in this 
area. 
5. Highlight any discussion and initiatives that have been 
\.U'ldertaken by ~ related to the Canadian 
academic/research 0001111mity or private sector. 
6. Prepare a stmnarY of donor policy and research 
initiatives in the area of biotechnology. 
\ 
7. Prepare a preliminary list and description of the major 
international institutional initiatives related to 
biotechnology that address the issues relevant to the 
deve lopj ng world • 
The consultant will begin his work next week. 
-- .,_ 
APPENDIX B 
Biotechnology Related Projects Funded by IDRC 
Over the last two decades approximately 9/. (351> of all IDRC 
projects <3997> and about 14/. ($97 million> of total IDRC 
expenditure ($709 million> have been in biotechnology related 
projects. In the period from 1985 to 1989 the number of 
biotechnology related projects has declined to 71., while 
expenditure on biotechnology related projects fell to ll'l.. 
The Agriculture, Food and Nutrition Sciences Division with 
$81,241,386.00 <81/.) has spent the lion's share of the total 
ex~enditure in biotechnology related projects; Health Sciences 
Division $11,677,625.00 <121.>; Earth and Engineering Sciences 
Division $2,368,251.00 <2.5'l.>; Fellowships and Awards Division 
Sl,155,120.00 <l'l.>; Social Sciences Division $43,500.00; and the 
Secretary's Office Sl58,700.00. Globally, the projects were 
distributed as foliows: Africa <30'l.>; Asia <28'l.>; Latin America 
<lO'l.>; Middle East <B'l.>; Central America <7'l.>; Oceania <0.5'l.>. 
Fifteen percent <151.> of the projects had a global focus. 
By Divisions and Programs the projects breakdown as follows: 
Agriculture, Food and Nutrition Sciences, 310 <B8'l.>, with 264 in 
Crops and Animal Production Systems; Forestry, 21; Forestry 
Integrated Production Systems, 6; Fisheries, 8; Cooperative 
Programs, 7; Post Production Systems, 3; Environment and 
Sustainable Resource Management, 1: Health Sciences, 43 <121.>; 
Tropical and Infectious Diseases, 24; Maternal and Child Health, 
12; Health and the Environment, 4; Water Supply and Sanitation, 
3: Earth and Engineering Sciences, 7 <2'l.>; Technology for Local 
Enterprises, 5; Other Fields, 2: Fellowships and Awards, 3; Group 
Training, 2; Training for Program Development, 1: Social 
Sciences, 1: Secretary's Office, 1. 
The key words, taken from the 1985 IDRC Manuscript Report, 
"Biotechnology: Opportunit_ies and Constraints," used to compile 
the list of biotechnology related projects funded by IDRC are as 
follows: nitrogen fixation, pest control, rhizobium, natural 
pesticides, hopital waste water, piggery waste treatment, 
biological pest management, genetic, tissue culture, crops and 
diseases, yellow dwarf, faba pathology, leaf spot, microbial 
protein, fish parasites, induced spawning, sperm, anticonceptive, 
bilharzia, mosquitoes, corneal eye, dengue, epidemiology, 
vaccines, lignocellulolitic fungi, bioconversion lignocellulose, 
enzyme production, genotyping, dissemination nitrog~n, law 
biotechnology, novel foods, symposium research biotechnology. 
Biotechnology Related Projects Funded by IDRC 
============================================================================================= 
AGRICULTURE, FOOD AND NUTRITION SCIENCES 
Crops and Animal Production Systems 
3-P-72-0011 I Sorghum Breeding, Intercropping and Grain Preservation 
3-P-72-0025 I Intercropping (Tanzania) - Phase I 
3-P-72-0051 I Sorghum Improvement (East Africa> - Phase 
3-P-72-0054 I Sorghum, Finger Millet, Pigeon Peas <Uganda) - Phase I 
3-P-72-0073 I Sorghum (CIMMYT> - Phase I 
3-P-72-0095 I Sorghum Improvement (Ethiopia) - Phase I 
3-P-72-0lGl I Drought Resistance <Laval) - Phase I 
Recipient: Universite Laval, Departement de Phytologie 
3-P-73-0010 I Sorghum, Millet, Legumes (ALAD> - Phase I 
3-P-73-0012 I Triticale <Chile> - Phase I 
3-P-73-0013 I Grain Legumes CICRISAT> - Phase I 
3-P-73-0050 I Triticale (Kenya> 
I Senegal I $957,600 
I Tanzania I $120,570 
/East Africa/ $76,000 
I Uganda I $195,050 
I Global I $70,170 
I Ethiopia I $195,300 
I Senegal I $76,800 
$680,300 /Middle East/ 






I Global 3-P-73-0129 I Drought Tolerance <Saskatchewan) - Phase I 
Recipient: University of Saskatchewan. Crop Development 
·-73-0136 I Cassava Mites CCIBC> - Phase I 
Research Centre 
3-P-73-0143 I Sesame (Israel> 
3-P-73-0145 I Rice Research CWARDA> - Phase I 
3-P-74-0004 I Triticale (India) 
3-P-74-0023 I Sorghum Improvement \Ethiopia) - Phase II 
3-P-74-0026 I Winter Triticale (Guelphl - Phase I 
Recipient: University of Guelph. Department of Crop Science 
3-P-74-0046 I Cassava <Malaysia> 
3-P-74-0054 I Varietal Screening \Philippines) - Phase I 
3-P-74-0107 I Drought Resistance <Laval> - Phase II 
Recipient: Universite Laval. Departement de Phytologie 
3-P-74-0132 I Sorghum <CIMMYT> - Phase II 
3-P-74-0160 I Grain Legumes <Caribbean) - Phase II 
3-P-74-0161 I Grain Legumes <ICRISAT> - Phase II 
3-P-75-0001 I Root Crops CUWI> - Phase II 
3-P-75-0026 I Cassava Mites <CIBC> -\Phase II 
3-P-75-0032 I Rapeseed <India) - Phase I 
3-P-75-0037 I Sorghum, Triticale, Oilseeds <Rwanda) 
3-P-75-0041 I Root Crops <Cameroon/ I ITA> - Phase I 
3-P-75-0072 I Millets <India> 
3-P-75-0088 I Sorghum <Seriega 1) - Phase I 1 
3-P-75-0094 I Cassava Microbiology <Guelph) - Phase 
3-P-75-0097 I Safflower <India> - Phase I 
3-P-75-0098 I Sesame <India) - Phase I 
- Phase 
I 
3-P-75-0110 I Sorghum, Finger Millet, Pigeon Peas <Uganda) 
0 -75-0114 I Mustard <India> - Phase I 
,,, -P-75-0116 I Sorghum/Millets CEAC> - Phase I I 
3-P-75-0122 I Crop Rotations <Kenya) 




I Global I 
I Israel I 
/West Africa/ 












































/East Africa/ $132,500 
I Kenya I $87,400 
I Asia I $440,000 
-75-0131 I Pigeon Peas <Kenya) 
3-P-76-0052 I Triticale Outreach (Ethiopia) - Phase II 
3-P-76-0078 I 9uinoa <Bolivia) - Ph••• I 
3-P-76-0105 I Cassava <Zanzibar> - Phase I 
3-P-76-0134 I Cold-Tolerant Sorghu• <ICRISAT> - Phase 
3-P-76-0148 I Winter Triticale (Buelph) - Phase II 
3-P-76-0149 I Triticale ("anitoba) 
Recipient: University of Manitoba. Faculty of Agriculture 
3-P-76-0160 I Cassava "ealy Bug <CIBC> - Phase I 
3-P-76-0191 I Grain Leguaes <Caribbean> - Phase III 
3-P-77-0041 I Striga (Sudan> - Phase I 
3-P-77-0048 I Grain Legu•e• (Bangladesh) - Phase I 
3-P-77-0049 I Root Crop& <Sri Lanka) - Phase I 
3-P-77-0060 I Food Legume lmproveaent (Sudan> - Phase I 
3-P-77-0073 I Food Legume Improveaent (Egypt> - Phase I 
3-P-77-0081 I Winter Triticale (Buelph> - Phase III 
3-P-77-0083 I Beans and "aize I•proveaent (Burundi> - Phaae I 
3-P-77-009i I Food Legumes (Niger) 
3-P-77-0101 I Grain Leguaes (!CARDA> - Phase I 
3-P-77-0102 I Food Legumes (Sierra Leone> - Phase I 
3-P-77-0125 I Pasture Legumes <ICARDA> 
3-P-77-0159 I Cowpea Storage <Upper Volta> - Phase I 
3-P-78-0032 I Pasture Legu•es <Panama) 
3-P-78-0035 I A•azonian Production Systeas <Peru> - Phase I 
3-P-78-0036 I Pasture Development <Chile) - Phase I 
-78-0039 I Plantains (Cameroon> - Phase I 
3-P-78-0040 I Food Legumes <Mali> - Phase I 
3-P-78-0041 I Orobanche Control <ICARDA> - Phase II 
3-P-78-0042 I Barley Improvement <Turkey> 
3-P-78-0043 I Grain Legumes <Algeria> - Phase II 
3-P-78-0044 I Oilseeds <Egypt) - Phase I 
3-P-78-0045 I Varietal Screening (Philippines> - Phase II 
3-P-78-0046 I Drought Resistant Crops (Catie) - Phase I 
3-P-78-0047 I Rice Research <WARDA> - Phase II 
3-P-78-0048 I Food Legumes <Turkey) - Phase I 
3-P-78-0092 I Cold-Tolerant Sorghua (ICRISAT> - Phase II 
3-P-79-0016 I Sorghum laprovement <Ethiopia) - Phase III 
3-P-79-0017 I Broundnut Improvement ("ozambique> - Phase I 
3-P-79-0022 I Wild Cassava <Brazil> 
3-P-79-0027 I Food Legume Drought Tolerance <IITA/Niger> 
3-P-79-0038 I Food Legumes <Upper Volta/IITA> - Phase II 
3-P-79-0040 I Root Crops <Congo Brazzaville> 
3-P-79-0052 I Triticale (Chile> - Phase III 
3-P-79-0063 I Pigeon Peas <Kenya) - Phase II 
3-P-79-0064 I Drought Tolerance <Saskatchewan> - Phase II 
Recipient: University of Saskatcheuan 
3-P-79-0065 I Cassava Mites <Trinidad) <CIBC> - Phase III 
3-P-79-0087 I Root Crops <Cameroon/IITA> - Phase II 
3-P-79-0090 I Food Legumes <Pakistan) 
3-P-79-0094 I Sorghum <Senegal> - Phase III 
~-79-0101 I Legumes Under Bananas <UPEB> 
~ ~-79-0104 I Oilseeds <Sri Lanka) - Phase I 
3-P-79-0134 I Grain Legumes <Bangladesh> - Phase II 
















I Brazil I 
I Caribbean I 
I Sudan I 
I Bangladesh/ 












I Burundi I 






I Peru I 
I Chile I 
I Ca11eroon I 
I Ma 1 i I 
/Middle East/ 
I Turkey I 
I Algeria I 
I Egypt I 
I Asia I 
/Central America/ 
I Senegal I 
I Turkey I 
I Global I 
I Ethiopia I 
I "oza11bique/ 
I Brazil I 
/West Africa/ 
/Burkina Faso/ 
I Congo I 
I Chi le I 
I Kenya I 








































I Sri Lanka I 
I Bangladesh/ 





-79-0142 I Pulses and Groundnuts <Tanzania) - Phaae I 
3-P-79-0144 I Grain Legu•es (!CARDA> - Phase II 
3-P-79-0172 I Food Legu•e Insect Control (Upper Volta> 
3-P-80-0009 I Faba Bean Diseases (Hanitoba> - Phase I 
Recipient: University of Manitoba. Depart•ent of Plant Science 
3-P-80-0056 I Sorghum/Hillets (Uganda) - Phase III 
3-P-80-0082 I Food Brain l•prove•ent <Sri Lanka) - Phase II 
3-P-80-0102 I Oilseeds <Sudan> - Phase I 
3-P-80-0103 I Sorghu• l•prove•ent <So•alia> - Phase I 
3-P-80-0115 I 9uinoa <Bolivia) - Phase II 
3-P-80-0116 I Cassava Healy Bug <CIBC> - Phase II 
3-P-80-0118 I Food Legu•e l•prove•ent <Egypt> - Phase II 
3-P-80-0131 I Highland Oil Crops l•prove•ent <Ethiopia) 
3-P-80-0161 I Food Legumes <IRRI/UPLB> 
3-P-80-0189 I Bananas <Philippines> - Phase I 
3-P-81-0001 I Cassava <Zanzibar> - Phase II 
3-P-81-0002 I Food Legu•es <IITA> - Phase III 
3-P-81-0006 I Food Legumes (Sierra Leone) - Phase II 
3-P-81-0025 I Cereals <Rwanda> - Phase II 
3-P-81-0057 I Hillet and Sorghu• <Zi•babwe> 
3-P-81-0079 I Sweet Potatoes <Philippines) - Phase I 
3-P-81-0089 ! Peas and Maize I•prove•ent (Burundi) - Phase II 
3-P-81-010! I Grain Legu•es (lcarda) - Phase III 
3-P-81-0113 I Striga (Upper Volta> - Phase II 
3-P-81-0114 I Food Legumes <Burkina Faso> - Phase III 
'-81-0115 I Pasture Development (Chile) - Phase II 
~-P-81-0117 I Oilseeds <Egypt> - Phase II 
3-P-81-0130 I Bamboo <China> - Phase I 
3-P-81-0133 I Tropical Pastures Network (Colombia) - Phase I 
3-P-81-0174 I Plantain Cropping Systems <Catie) - Phase I 
3-P-81-0175 I Root Crops <Liberia) - Phase I 
3-P-81-0183 I Rice Research <Warda> - Phase III 
3-P-82-0012 I Vegetable Seed <Thailand> - Phase I 
3-P-82-0013 I Intercropping (Swaziland> - Phase II 
3-P-82-0014 I Groundnut Improve•ent <Thailand> - Phase I 
3-P-82-0015 I Erythrina <Catie> - Phase I 
3-P-82-0059 I Mustard <India) - Phase II 
3-P-82-0060 I Rapeseed <India) - Phase II 
3-P-82-0061 I Safflower <India) - Phase II 
3-P-82-0062 7 Sesame <India> - Phase II 
3-P-82-0073 I Root Crops (Congo-Braz~aville) - Phase II 
3-P-82-0084 I Plantain I Banana Improve•ent <Ja•aica> 
3-P-82-0088 I Tropical Pasture Evaluation <Ecuador) - Phase I 
3-P-82-0093 I Groundnut Improvement <Hozambique> - Phase II 
3-P-82-0094 I Striga <Sudan> - Phase II 
3-P-82-0096 I Lo~land Oil Crops I~prove•ent <Ethiopia) 
3-P-82-0098 I Cassava and Sweet Potato <Rwanda) - Phaae I 
3-P-82-0137 I Lignocellulolytic Fungi <Thailand) - Phase II 
3-P-82-0139 I Pigeon Pea• (Kenya> - Phase III 
3-P-82-0144 I Rapeseed <China> 
P-82-0154 I Biological Pest Hanage11ent <India> - Phaae I 
P-82-0179 I Tropical Pasture Evaluation <Colombia) 
3-P-82-0180 I Tropical Pasture Evaluation <Pana•a> 
3-P-82-0186 I Food Legu•es <Indoneaia> - Phase I 
4 
I Tanzania I $321,205 
/Hiddle East/tl,050,000 
/Burkina Faso/ t144,300 
I Global I SJ14,300 
I Uganda I 
I Sri Lar.ka I 
I Sudan I 
I So•alia I 
I Bolivia I 
/Latin A111erica/ 
I Egypt I 
I Ethiopia I 
I Asia I 
/Philippines/ 
I Tanzania I 
/West Africa/ 
/Sierra Leone/ 
I Rwanda I 
I Zi11babwe I 
/Philippines/ 
I. Burundi I 















































I Liberia I 
/West Africa/ 
I Thailand I 
I Swazi land I 
I Thailand I 
I Costa Rica/ 
I India I 
I India I 
I India I 
I India I 
I Congo I 
I Jamaica I 
I Ecuador I 
I Mozambique/ 














I $471, 732 
I t139,BOO 
I $230,000 
I $602 1 900 
I f128, 100 
I $127,000 
I 
I Indonesia I 
'78,600 
$234,500 
-82-0187 I nillets (India) - Phase II 
3-P-82-0188 I Vegetables <China> 
3-P-82-0190 I Fish Parasites <"alaysia) - Phase II 
3-P-82-0198 I Fish Parasites <Indonesia) - Phase II 
3-P-82-0256 I Food Legu•es (llTA> - Phase IV 
3-P-83-0008 I Sorghu• l•prove•ent <So•alia) - Phase II 
3-P-83-0022 I Plantains <Ca•eroon) - Phase II 
3-P-83-0025 I Food Legu•es <Mali> - Phase II 
3-P-83-0035 I Sweet Potatoes <Philippines> - Phase II 
3-P-83-0079 I Potatoes fro• Seed <Egypt> 
3-P-83-0111 I Dairy Production Syste•s (Sudan> 
3-P-83-0122 I Food Legu•e I•prove•ent <Sudan) - Phase II 
3-P-83-0123 I Food Legu•es North Africa <ICARDA> 
3-P-83-0128 I Pracipa Network <CIP> - Phase I 
3-P-83-0132 I Root Crops (Cameroon/IITA> - Phase III 
3-P-83-0133 I Root Crops <Uganda} 
3-P-83-0143 I Cassava nites <Eastern Africa> CIBC> - Phase IV 
3-P-83-017~ I Oilseeds Network <Ethiopia> - Phase II 
3-P-83-0182 I Striga <Upper Volta> III 
3-P-83-0199 I Root Crops <Sri Lanka> - Phase II 
3-P-83-0211 I Lentil/Chickpea Improve•ent Mechanization - Phase II 
3-P-83-0215 I Peas and Maize Iaprove•ent <Burundi> - Phase III 
3-P-83-0217 I Tropical Pastures Network (Colo~bia) - Phase II 
3-P-84-0039 I Highland Oilcrops I•prove•ent <Ethiopia) - Phase II 
3-P-84-0113 I Coffee Berry Borer (CIBC/"exico> 
'-84-0136 I Broundnuts ("alawi> - Phase II 
~-P-84-0137 I Oilseeds (Sudan> - Phase II 
3-P-84-0149 I l•proved Crops for Small Farmers <Chile) - Phase I 
3-P-84-0219 I Sorghum and Millets (Uganda> - Phase IV 
3-P-84-1020 I Soy Rhizobia <Alberta/Thailand) 
Recipient: Agriculture Canada, Soil Science Section (Lethbridge> 
3-P-84-1035 I Faba Bean Pathology <Manitoba I !CARDA> - Phase III 
Recipient: University of Manitoba, Department of Plant Science 
3-P-84-1042 I Lentil Haploids <Manitoba I ICARDA> 
Recipient: University of Manitoba 
3-P-84-1053 I Oilseed Anther Culture <Agriculture Canada/Network> 
Recipient: Agriculture Canada, Research Station 
3-P-84-1055 I Faba Bean Pollination <nanitoba /ICARDA> 
Recipient: University of Manitoba, Faculty of Agriculture 
3-P-84-1058 I Root Crop <Montreal/Ivory Coast> 
Recipient: Universite de Montreal ~ 
3-P-85-0010 I Vegetable Seed Production <Thailand) - Phase II 
3-P-85-0012 I Quinoa <Bolivia> - Phase III 
I India I t435,900 
I China I t4B0,410 
I Malaysia I t170,500 
I Indonesia I 5382,800 
/West Africa/ $618,516 
I Somalia I 5479,500 
I Ca•ero~n I 5174,900 
I Mali I f198,920 
/Philippines/ S439,900 
I Egypt I 5204,400 
I Sudan I $255,600 
I Sudan I $265,200 
/North Africa/ $599,300 
/Andean Region/ $504,000 
I Cameroon I $455,700 
I Uganda I 5330,400 
/East Africa/ 5140,100 
I Global I SS15,BOO 
/Burkina Faso/ $300,000 
I Sri Lanka I S287,400 
I Jordan I S350,690 
I Burundi I S540,400 
/Latin America/ $737,100 
I Ethiopia I $337,500 
I Hexico I $401,400 
/Southern Africa/ S752,400 
I Sudan I $309,740 
I Chile I $307,200 
I Uganda I S382,500 
I Thailand I $483,000 
I Global I Sb48,500 
I Global I S146,600 
I Global I $119,100 
I Global I $99,000 
/Cote d'Ivoire/ $128,002 
I Thailand I 
I Bolivia I 
I Hondura& I 3-P-85-0013 I Plantain/Banana laprove•ent <Honduras) 
3-P-85-0015 I Root and Plantain Cropping Syste•s <CATIE>-Phase 
3-P-85-0018 I Grain Legumes (Bangladesh> - Phase III 
3-P-85-0019 I Pulses and Groundnuts <Tanzania) - Phase II 
3-P-85-0022 I Millets CBan~ladesh> - Phase II 
3-P-85-0027 I Food Legu•es <Pakistan> - Phase II 
II /Central A•erica/ 
I Bangladesh/ 
I Tanzania I 
I Bangladesh/ 











3-P-85-0050 I Food Legumes <IITA> - Phase V 
- P-85-0092 I Groundnut lmprove•ent (Thailand) - Phase II 
?-85-0129 I Food legu•es <IRRl/UPLB> - Phase II 
3-P-85-0134 I Grain Legumes <Nepal> 
3-P-85-0138 I Quinoa Production (Ecuador> - Phase II 
5 
, /West Africa/ 







-85-0167 I Pasture Network for Eastern and Southern Africa <PANESA>I Africa I t400,000 
3-P-85-0191 I Food Legu••• <Turkey> - Phase II I Turkey I S198,200 
3-P-85-0192 I Roots and Tubers <Zanzibar) - Phase III I Tanzania I t175,000 
3-P-85-0222 I Cassava and SMeet Potato <Rwanda) - Phase II I RManda I S245,000 
3-P-85-0339 I Tissue Culture CColo•bia> I Colo•bia I t50,300 
3-P-85-1047 I Biological Control <Buelph/China) I Global I S449,700 
Recipients University of Buelph. Departaent of Environ•ental Biology 
3-P-85-1012 I YelloM Dwarf Virus <Laval> - Phase II I Global I S147,402 
Recipient: Universite Laval, Departe•ent de phytologie 
3-P-85-1050 I "icrobial Control <Agriculture Canada/Egypt> - Phase I I Global I S388,400 
Recipient: Agriculture Canada, Research Station 
3-P-86-0012 I Cassava "ites <Eastern Africa/CIBC> - Phase V 
3-P-86-0089 I Food Grain l•prove•ent <Sri Lanka> - Phase III 
3-P-86-0.092 I Oil-Crops for Reclai•ed lands <Egypt> - Phase III 
3-P-86-0099 I Soybeans <Pakistan) 
3-P-86-0105 I Bananas/Plantains So•aclonal "utation (CATIE> 
3-P-86-0115 I Tropical Pasture Evaluation <"exico) 
3-P-86-0124 I Andean Crops/Livestock Systeas <Peru> - Phase III 
3-P-86-0191 I Trifolium Rhizobia <UBC/ILCA> 
Recipient: University of British Colu•bia. Depart•ent of Plant 
3-P-86-0200 I Bananas <Philippines> - Phase II 
3-P-86-0212 I Maize and Peas <Burundi) - Phase IV 
3-P-86-0224 I Pigeon Peas CKenya> - Phase IV 
3-P-86-0233 I Biological Pest "anage•ent <India> - Phase II 
3-P-86-0241 I PRACIPA Network <CIP> - Phase II 























I Burundi I 
/-Kenya I 
I India I 
/Andean Region/ 
















S335,200 ~-f-86-1016 I Rhizobial Carrier Syste•s <"anitoba/ICARDA> - Phase II 
Recipient: University of "anitoba, Department of Plant Science 
3-P-86-1020 I Yellow DMarf Virus <Laval/ICARDA/Chile) - Phase III I Global I S335,000 
Recipient: Laval University, Department of Phytology 
3-P-86-1049 I Aphid Biocontrol <ABN/China) I China I $56,200 
Recipient: Applied Bio-Nomics ltd. <ABN> (Sidney, B.C.> 
3-P-86-1046 I Rapeseed <Agriculture Canada/China> - Phase II I China I S554,300 
Recipient: Agriculture Canada, Research Branch 
3-P-87-1009 I Leaf Spot <Alberta/Costa Rica) - Phas~.II I Costa Rica/ S328,700 
Recipient: University of Alberta, Department of Che•i&try 
3-P-87-1010 I Weevil Resistance <Ottawa/CIHMYT/Mexico/Zimbabwe) Phase II/ Global I S278,400 
Recipient: University of Ottawa, Centre for Graduate Studies and Research in Biology 
3-P-87-1014 I Bacillus Thuringiensis Elisa CUWO> I Global I $28,600 
Recipient: University of Western Ontario, Faculty of Engineering Science 
3-P-87-1022 I Botanical Pesticides <Bttawa/Philippines> /Philippines/ $301,800 
Recipient: University of OttaMa, Faculty of Science ~ 
3-P-87-0133 I Integrated Pest Management <Philippines) /Philippines/ $108,100 
3-P-87-0007 I Plantain Production Improvement <Colombia) I Colombia I $246;600 
3-P-87-0021 I Hill Crops <Nepal> I Nepal I S485,000 
3-P-87-0025 I Oilseeds Network <Ethiopia) - Phase III I Global I $557,811 
3-P-87-0026 I Peach Palm and Aroids (Costa Rica> I Costa Rica/ $336,900 
3-P-87-0038 I Groundnut I•prove•ent ("ozambique> - Phase III I Moza~bique/ $501,bOO 
3-P-87-0039 I Oilseeds (Sri Lanka) - Phase II I Sri Lanka I $202,400 
3-P-87-0070 I Sesame Research <India> / India I $96,900 
- 0 -87-0132 I Food Legumes <Hali) - Phase III I Mali I $259,800 
'-87-0201 I Banana and Plantain Network <INIBAP> - Pha&e IV I Global I S150,000 
3-P-87-0233 I Tropical Pa&ture& Network <CIAT> - Phase III /Latin America/ $671,600 
3-P-87-0246 I Vegetables <China> - Phase II I China I 1454,600 
6 
-87-0255 I Oil Crops <Ethiopia) 
3-P-87-0261 I Triticale (Syria> 
3-P-87-1043 I Leucaena Psyllid Bio-Control (AEC/ASIA/CIBC> 
Recipient: Alberta Environ•ental Centre (AEC> 
3-P-88-0020 I Vegetable Seed Production (Thailand> - Phase III 
3-P-88-0021 I Sesa•e for Rice-based Far•ing Syste•s <Philippines> 
3-P-88-0024 I Food Legu•es <Indonesia> - Phase II 
3-P-88-0063 I Highland Sweet Potatoes <Philippines> 
3-P-88-0081 I Eucalyptus I•prove•ent <Chile> 
3-P-88-0114 I Root Crops <Liberia) - Phase II 
3-P-88-0117 I Banana Cropping Systems <Uganda) 
3-P-88-0146 I Root Crops <Halawi> 
3-P-88-1004 I Rapeseed/Mustard <Agriculture Canada/India> 
I Ethiopia I 
I Syria I 
I SE Asia I 
I Thai land I 
/Philippines/ 
I Indonesia I 
/Philippines/ 
I Chile I 
I lib er i a I 
I Uganda I 
I Malawi I 
I India I 













3-P-88-1043 I Microbial Control <Agriculture Canada/Egypt> - Phase II I Global I S496,900 
Recipient: Agriculture Canada, Research Branch <Ottawa> 
3-P-89-1012 I Botanical Pesticides <Ottawa/Thailand/UBC> I Thailand I S419,600 
Recipien~: University of Ottawa, Faculty of Science 
3-P-75-0048 I Casuarina <Egypt> - Phase I 
3-P-77-0008 I Pine Beetle <Guatemala) 
3-P-79-0026 I Bamboo <Bangladesh> 
Forestry 
3-P-82-0069 I Tree Seed Improvement <Ecuador> 
~-82-0121 I Paulownia <China> 
~-P-83-0059 I Nitrogen-Fixing Trees (Sierra Leone) 
3-P-83-0106 I Cowpea Storage <Sierra Leone> - Phase II 
3-P-83-0288 I Rattan (Indonesia> - Phase I 
3-P-83-0296 I Bamboo (Bangladesh> - Phase II 




I Ecuador I 
I China I 
/Sierra Leone/ 
/Sierra Leone/ 
I Indonesia I 
I Bangladesh/ 
I Malaysia I 
/Sierra Leone/ 
I Colo11bia I 
/Philippines/ 
I Colo1Abia I 
3-P-84-0088 I Root Symbiosis <Sierra Leone> 
3-P-85-0009 I Tree Seed Improvement <Colombia> 
3-P-85-0105 I Bamboo Tissue Culture <Philippines) 
3-P-85-0112 I Forest Tissue Culture <Colombia) 
3-P-85-0186 I Erythrina (CATIE> - Phase II 
3-P-85-0263 I Multi-purpose Trees (India> 
/Central America/ 
3-P-85-0264 I Prosopis <Brazil> 
3-P-86-0148 I Acacia Root Symbiosis <Tunisia> - Phase I 
3-P-87-0236 I Tissue Culture <India> 
3-P-88-0003 I Chachafruto <Colombia>\- Phase I 
J-P-89-1016 I Acacia Root Symbiosis <Laval/Tunisia> - Phase II 





.. ·P-88-0293 I 
?-89-0052 I 
Forestry -- Integrated Production Systems 
Paulownia <China> - Phase II 
Acacia Albida <Burkina Faso> 
Rattan <Malaysia> - Phase II 
Prosopis (Argentina> 
Forest Tree Culture <Egypt> 
MPT Tissue Culture <ILCA> 
Fisheries 
7 
I India I 
I Brazil I 
I Tunisia I 
I India I 
I Colombia I 
I Tunisiiil I 
I China I 
/Burkina Faso/ 
I Malaysia I 
I Argentina I 
I Egypt I 




























3-P-73-0147 I Fish Parasite• <Indonesia) - Phase I 
3-P-79-0069 I Fish Parasites <Philippines> 
3-P-79-0085 I Fish Parasites <Halaysia> - Phase I 
3-P-82-1015 I Carp Genetics <Dalhousie/Indonesia> - Phase II 
Recipient: Dalhousie University, Research Services 
3-P-83-1011 I Induced spawning <Alberta/China> 
Recipient: University of Alberta, Depart•ent of Zoology 
3-P-85-1051 I Fish 8enetics Net"ork <Dalhousie/Asia> 
Recipient: Dalhousie University 
3-P-86-0030 I Fish Genetics <Thailand) - Phase II 
3-P-87-1028 I Induced Spawning <Alberta/China/Guelph) - Phase 
Recipient: University of Alberta, Depart•ent of Zoology 
Cooperative Programs 
3-P-81-1001 I Hicrobial Protein <Guelph) 
Recipient~ University of Guelph, Depart•ent of Hicrobiology 
3-P-81-1005 I Yellow dwarf virus <Laval) - Phase I 
I I 
Recipient: Universite Laval, Departement de Phytologie 
3-P-82-1001 I Faba Bean Pathology <Hanitoba) - Phase II 
Recipient: University of Manitoba, Depart•ent of Plant Science 
3-P-82-1002 I Rhizobial Ca~rier Systems <Manitoba) 
Recipient: University of Manitoba, Depart•ent of Plant Science 
3-P-83-1031 I Genotyping <Manitoba I CIAT> 
cipient: University of Manitoba, Department of Plant Science 
3-, -83-1032 I Tissue Culture <Calgary I Costa Rica> 
Recipient: University of Calgary, Depart•ent of Biology 
3-P-84-1006 I leaf Spot (Alberta/Costa Rica> 
Recipient: University of Alberta, Department of Chemistry 
Post Production Systems 
3-P-73-0009 I Grain Storage <Ghana> 
3-P-80-0125 I Faba Beans <Egypt> - Phase II 
3-P-83-1004 I Natural Pesticides <Carleton University> 
Recipient: Carleton University, Departaent of Biology 
Environment and Sustainable Resource Manage•ent 
3-P-89-0071 I Agroforestry Seed Cleari.ng House <Philippines> 
I Indonesia I $235,300 
/Philippines/ $24,BOO 
I Halaysia I $18,400 
I Indonesia I $383,700 
I China I $375,381 
I Asia I $640,278 
I Thailand I t375,300 
I China I $287,500 
I Blobal I $133,850 
I Blobal I $162,000 
I Global I $193,286 
/Middle East/ fl 70, 300 
I Global I $337,500 
I Costa Rica/ $202,500 
I Costa Rica/ $382,800 
I Ghana I $22,700 
I Egypt I $160,200 




Tropical and Infectious Diseases 
~ ·76-0184 I Bilharzia <Egypt> - Phase I 
3-P-78-0069 I Dengue Hemorrhagic Fever Surveillance <Indonesia> 
3-P-79-0123 I Dengue Hemorrhagic Fever Sulawesi <Indone~ia) 
8 
I Egypt I S51,549 
I Indonesia I S137,500 
I Indonesia I S29,650 
~ r-80-0194 I Bilharzia <Egypt> - Phase II 
3-P-81-1002 I Bio-control of "osquito5 <South Pacific> - Phase I 
Recipient: Me•orial University of NeNfoundland <"UN> 
3-P-82-0107 I Dengue He•orrhagic Fever <Cuba) 
3-P-82-0223 I Bilharzia <Egypt> - Phase III 
3-P-82-0225 I Yellow Fever <Latin America> - Phase I 
3-P-82-1008 I Bio-control of Hosquitos <South Pacific> - Phase II 
Recipient: "e•orial University of Newfoundland <MUN> 
3-P-83-0087 I Conference on Dengue/Dengue Hemorrhagic Fever <DF/DHF> 
3-P-83-0140 I Tuberculosis <Korea> 
3-P-83-0213 I Hepatitis B (Malaysia> 
3-P-83-1029 I Corneal Eye Infections <Nepal) 
Recipient: University of Calgary 
3-P-84-0033 I Epide•iology of Dengue <rtalaysia) - Phase I 
3-P-84-0054 I B. C. 6. Vaccination <Kenya> 
3-P-84-0079 I Vaccine Trial Centre <Thailand> 
3-P-85-0042 I Yellow Fever <Latin A•erica> - Phase II 













Dengue Haemorrhagic Fever <Cuba) - Phase II 
Determinants of Dengue <Mexico) 
Diagnosis of Dengue <Malaysia) 
Epidemiology of Dengue <Malaysia) - Phase II 
Bilharzia <Egypt) - Phase IV 
Yellow Fever Vaccine <Nigeria> 
Maternal and Child Health 
3-P-75-0106 I Anticonceptive Technology <ICCR II/India) - Phase I 
3-P-78-0021 I Sperm Inhibition <Chile) - Phase I 
Recipient: Queen's University. Department of Biochemistry 
3-P-79-0132 I Initiation of Sperm Motility <Thailand> - Phase I 
3-P-79-0150 I Antioconceptive Technology - ICCR <India) - Phase II 
3-P-80-0069 I Time-Temperature Indicators <Global> - Phase I 
3-P-80-0090 I Sperm Inhibition <Chile> - Phase II 
Recipient: Queen's University. Department of Biochemistry 
3-P-81-0023 I Time-Temperature Indicators <Global> - Phase II 
Recipient: lnstitut Armand-Frappier <IAF> Quebec 
3-P-82-0008 I Initiation of Sperm Motility <Thailand) - Phase II 
3-P-82-0155 I Anticonceptive Technology - ICCR <India> - Phase III 
3-P-83-1006 I Sperm Inhibition <Chile) - Phase III 
I Egypt I t66,2SS 
I Oceania I t:S3,500 
I Cuba I t16:S,100 
I Egypt I t246,086 
/Latin America/ $312,610 
I Ocean iii I S3S,400 
i Global I S45,030 
I Korea I f136,0SO 
I Malaysia I f75,120 
I Nepal I $143, 140 
I Malaysia I $143,675 
I Kenya I $113, 434 
I Thai land I t191,435 
/Latin America/ t215,455 
I Honduras I S85,620 
I Cuba I $114,290 
I Mexico I t143,900 
I Malaysia I $135,870 
/,'1alaysia I s100,s50 
I Egypt I t356,0BO 
I Nigeria ltl,155,120 
I India /S3,000,000 
I Global I S128,00S 
I Thailand I $61,600 
I Global I S550,000 
I Global I $75,000 
I Global I t209,500 
I Global I $163,100 
I Global I $66,600 
I Global I $711,320 
I Global I $466,420 
Recipienti Queen's University. Department of Biochemistry 
3-P-85-0261 I Anticonceptive Technology - NII/ICCR <India> - Phase 
3-P-85-0302 I Inhibition of Sper• Motility <Thailand) - Phase III 
3-P-86-1018 I Sperm Inhibition <Chile/Canada) - Phase IV 
IV I Global /Sl,058,000 





Health and the Environment 
Diagnosis of Dengue <Brazil> 
Corneal Eye Infections <Nepal> - Phase II 
Measles l•munization <Philippines) 
Anticonceptive Technology - NII <India) - Phase V 
9 
I Global I $91,420 
I Global I $130;137 
I Brazil I 
. I Nepal I 
/Philippines/ 





Water Supply and Sanitation 
3-P-76-0141 I Piggery Waste Treat•ent (Singapore> - Pha5e I 
3-P-79-0071 I Piggery Waste Treat•ent (Singapore> - Phase II 
3-P-83-0156 I Piggery Waste Treat•ent (Malaysia> 
EARTH AND ENBINEERING SCIENCES 
Technology for local Enterprises 
3-P-85-1016 I Biogas Refrigerator (China> 
Recipient: Canadian Bas Research Institute 
I Singapore I S302,984 
I Singapore I S302,500 
I Malaysia I S85,600 
I China I $269,385 
3-P-85-1033 I Technology Adoption SMEs (Malaysia> - Phase II I Malaysia I $262,000 
Recipien~: Saskatchewan Research Council I University of Saskatchewan, College of Co•merce 
3-P-87-1024 I Sugar Cane Waste Utilization CCuba> I Cuba I S441,000 
Recipient: University of British Colu•bia, Depart•ent of Chemistry 
3-P-87-1034 I Technology Adoption SMEs (Thailand> 
Recipient: University of Saskatchewan, College of Co••erce 
3-P-87-1051 I Partial Carbonization of Peat (Burundi> 
I Jhailand I $214,200 
I Saskatc~wan Research Council 
I Burundi I $145,365 
Recipient: Societe d'ingenierie Cartier Li•itee (Montreal> 
~-87-1052 I Technology Adoption by SMEs in Singapore I Singapore I $216,250 
,,ecipient: University of Saskatchewan, College of Commerce I Saskatchewan Research Council 
Other Fields 
3-P-84-1048 I Technology Adoption SMEs <Malaysia) I Malaysia I $129,881 
Recipient: Saskatchewan Research Council I University of Saskatchewan, College of Com•erce 
3-P-85-1038 I Industrial Waste Treatment Biogas <India) I India I $690,170 
Recipient: National Research Council of Canada CNRC> I Carleton University 
:=============================================c=======================2=========s====c===z=== 
FELLOWSHIPS AND AWARDS 
·--------------------------------------------------------------------------------------------\ 
Group Training 
3-P-85-0219 I Training Course: Insect Pest Management - Phase I I Africa 
3-P-85-0237 I Training: Varietal Testing & l•provement of Oryland Legume/ Asia 
Training for Program Development 
















Technology Policy !3rancll, ISTC 




National Biotechnology Advisory Committee 
Interdepartmental Corarnittee on Biotechnology 
Contact: M. Louise McArthur - 613/993-6045 
IRAP - BIOTECHNOLOGY FUNDING PROGRAM 
Dr. Denys Cooper - 613/993-5539 
General Manager, IRAP & Laboratory Network 
National Research Council of Canada 
THE NATIONAL BIOTECHNOLOGY NETWORKS 
DEPARTMENT(S) COORDINATOR(S) 
Or. L.R. Barran 
Agriculture Dr. R. Watson 
Plant Strain Canada 
Development Dr. W. Keller 









Animal Health and Welfare Dr. Keith Bailey I 613/9~)7-1052 
Care Products 
Agriculture Dr. J. Pantekoek 1613/995-5' 32' 
Mineral 
Leaching and Energy, Mines I 
Metal Recovery and Resources Dr. R.G.L. McCretady 613/9'.?2-l:::.SG i 
i 
I 
613/993-76591 Forestry and National Mr. W. Campbell 
Forest Research I 
Products Council I 
Waste National Dr. P. Matteau 613/993-7630! 
Treatment Research I Council I 
Environment Mr. s. Hart 613/994-21031 
Canada 
613/990-02751 Fisheries/ Fisheries and Ms. I. Price 




3-P-82-0120 I Dissemination of Biological Nitrogen Fixation Technology/ Kenya I 543,500 
================================~=••~m•===c================================•==•=•==csms•a=== 
SECRETARY'S OFFICE 
3-P-82-0043 I law and Biotechnology I Global I t158,700 
\ 
11 
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